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  3  4SUMMARY 
 
This work concerns cystatin B, a protein described as an antiprotease involved 
in Progressive Myoclonus Epilepsy of the Unverricht-Lundborg type (EPM1). In 
this neurodegenerative disorder, patients suffer from myoclonic jerks, tonic-
clonic seizures, and progressive decline in cognition. The most common 
mutation described in EPM1 patients is the expansion of an unstable dodecamer 
in the cystatin B promoter. This sequence, repeated up to 75 times, is found in 
homozygosis or in heterozygosis together with an allele carrying a point 
mutation. Pennacchio et al [1] have shown that the knockout of the cystatin B 
gene generates a neurological disorder in mice, characterized by symptoms 
similar to those observed in EPM1 patients concluding that cystatin B protects 
CNS neurons against apoptosis and EPM1 is a loss of function disease. This 
function seems to be specific to the CNS, since in other tissues and cell types, 
the absence of cystatin B does not result in a pathological phenotype. 
On the other hand, cystatins have been implicated in a number of diseases. A 
variant form of cystatin C is the major constituent of amyloid plaques in the 
brain of patients with hereditary cystatin C amyloid angiopathy. Increased 
cystatin A and B is described in the plaques of Alzheimer's and Parkinson's, and 
of patients suffering from senile dementia, suggesting that they are amyloid 
constituents. Interestingly, proteins of the cystatin family are used as models for 
in vitro studies of amyloid fiber structure and Staniforth et al.[2]
 have shown 
that cystatins form highly stable domain-swapped dimers in vitro. 
Furthermore, Di Giaimo et al. [3]
 have isolated a number of cytoskeletal proteins 
interacting with cystatin B, none of which is a protease. Among them, the 
RACK-1 receptor of activated PKC, the brain beta spectrin and the 
neurofilament light chain form a multiprotein complex with cystatin B in the 
cerebellum. With a different approach, we have identified more cystatin B 
  5partners that also interact with each other and are involved in the same cellular 
process, the cytoskeletal function. Altogether, our data draw cystatin B in the 
Ca2+-mediated cytoskeletal activity, and in particular in vesicle traffic at the 
membrane level. This function is at the basis of neuronal signal transmission.  
By immunoprecipitation experiments, we show that the Δ68 EPM1 mutant of 
cystatin B does not interact with RACK-1, indicating that this mutation changes 
the structure of the multiprotein complex. 
This work shows for the first time that cystatin B has a polymeric structure in 
vivo both in eukaryotes and in prokaryotes. The polymeric pattern consists of a 
dimer, oligomers, and polymers larger than 100 kDa. Mass spectrometry 
analysis of the polymers immunoprecipitated from a protein cell extract 
demonstrates that the polymers contain cystatin B only. The polymers are highly 
resistant to SDS and urea denaturation and boiling. They are sensitive to 
reducing agents and alkaline pH. Hydrogen peroxide increases the polymeric 
structure of the protein.  
As already mentioned above, a similar pattern is observed expressing cystatin B 
in E. coli. Since cystatin B is an eukaryotic protein, E. coli offers a background 
free system to study the molecular mechanism of polymer formation. By column 
chromatography, we have fractionated E. coli protein extract and identified a 
factor that allows oligomer formation from cystatin B monomers in vitro. We 
are now characterizing the factor by mass spectrometry. Ultimately, we would 
like to isolate the corresponding mammalian protein for further studies. 
The analysis of natural and laboratory mutants of cystatin B shows that they are 
polymeric. The structural organization of the polymers changes when a cysteine 
minus mutant is transfected into the cells. This mutant does not generate stable 
oligomers of intermediate molecular weight but mainly dimer and polymers 
larger than 100 kDa. We have also shown that the cystatin B oligomers have 
rather alkaline isoelectric point that makes them unstable at physiological pH.  
  6Following 24-hour transfection in neuroblastoma cells, EPM1 and truncation 
mutants constructed in the laboratory generate cytoplasmic aggregates. In 
addition, the expression, in the same cell line, of wt cystatin B generates 
aggregates. In contrast, transfection of neuroblastoma cells with the cysteine 
minus mutant is less effective in aggregate formation. This may correlate with 
the absence of oligomeric cystatin B in this mutant. 
We conclude that cystatin B in vivo has a polymeric structure, regulated by the 
redox microenvironment of the cell and that over-expression of the wt protein 
and its mutants results in the generation of toxic aggregates. The results 
envisage a molecular mechanism that could explain neural degeneration at least 
in the EPM1 patients heterozygous for both promoter and point mutations.  
 
  7  8INTRODUCTION 
 
1. CYSTATIN B 
Cystatin B (CSTB) is a widely distributed protein found in most cell types and 
tissues where it may inhibit cysteine proteases of the cathepsin family [4-11]. It 
belongs to the cystatin super family, which includes a large number of proteins 
originated from an ancestral peptide [7-9]. 
The CSTB gene (see Appendix A) is located on human locus 21q22.3, within the 
Down syndrome region, has telomeric-centromeric orientation and is organized in 3 
short exons and 2 introns [9], alike all genes of the cystatin super family. The wt 
promoter, at position –210/–174, contains 2-3 tandem copies of the polymorphic 
dodecamer (C4GC4GCG)  [12]. Rarely the dodecamer is repeated 12-17 times 
(“premutated alleles”) [13-14]. The CSTB gene has a typical “housekeeping” 
promoter (high GC and CpG content, Sp1 sites) without CAAT o TATA boxes [15].  
 
1.1. THE PROTEIN 
CSTB belongs to the stefin family (or type I cystatins), which is a subset of the 
cystatin super family [7-9]. Stefins are defined as monomeric proteins with a 
(molecular weight) MW of about 11 kDa, missing intramolecular disulfur 
bridges or glycosilation [16].  
Figure 1 shows the X-ray crystal structure of recombinant human CSTB 
described by Stubbs et al. [17]. Structurally, CSTB consists of a five stranded β-
sheet wrapped around a five turn alpha helix, with an additional C-terminal 
strand running on the convex side of the sheet [17]. 
Most of the structural studies are focused on the properties of the domains that 
in vitro interact with the proteases. They form a hydrophobic surface that 
  9includes the motives conserved in all the inhibitory cystatins of the super family, 
although there are some characteristics peculiar of CSTB.  
The N-terminal region misses the first 5 aminoacids, that in other cystatins are 
important for papain inhibition, but conserves the Gly4 [17-18]. The only cysteine in 
the molecule, at position 3
1, contributes to the binding of the proteases and may form a 






Figure 1. Crystal structure of human CSTB (PDB entry 1STF). Peptides coded by exon 1 in 
red, by exon 2 in green and by exon 3 in blue. The arrows indicate the position of the 
aminoacids conserved in the cystatin family: Gly 4, loop QXVXG (QVVAG in CSTB) between 
the β-strands 2 and 3 and loop PW (PH in CSTB) between β-strands 4 and 5. The position of 3 
EPM1 mutants is indicated (see Table 1). 
 
Of the two hairpin loops, loop 1 is characterized by the glutamine-X-valine-X-
glycine (QXVXG) motif
2 and loop 2 by the proline- histidine (PH) sequence, 
which substitutes the proline-tryptophane (PW) consensus, typical of the super 
                                                 
1 Most CSTB molecules contain only one Cysteineat position 3, rat and mouse CSTB contain both the conserved 
Cys3 and a second Cysteineat position 64 [10] 
2 QVVAG in man [25,9], in 9 mammalian cystatin B and in most of the Superfamily [10,27], QIVAG in mouse 
[10], QLVAG in bovine [26]. 
  10family. Single amino acid substitution experiments in loop 1 [23-24] and loop 2 
[26], show that the binding between CSTB and proteases of the cysteine family 
is stabilized by the hydrophobicity and steric geometry of the whole interacting 
surface and not by few specific aminoacids. Thus, the high sequence 
conservation of the two loops may be due to their involvement in a different but 
equally critical function of cystatins [23]. The C-terminal extension of CSTB, 
absent in other cystatins, contributes to such interaction generating an additional 
hydrophobic contact region which could compensate for the absence of the first 
N-terminal aminoacids [26].  
Cystatin, in all known cases, is a compact single-domain protein that, in 
agreement with the experimental results, is rather resistant to proteolytic 
cleavage. The N-terminal segment is essentially the only region accessible to 
protease attack [28]. 
Despite the considerable sequence similarity, CSTB shows stability and folding 
properties markedly different from cystatin A. In fact, while cystatin A is 
termostable and folds with a 2-state kinetic, CSTB is in a population of “molten 
globule” states under various partially unfolding conditions due to chemical, 
thermal or acid induced denaturation [29-33]. “Molten globules” show native-
like secondary structure and compactness (globular), lack persistent tertiary 
interactions such as the asymmetric environment due to aromatic amino acid 
residues (molten) and unfold through a noncooperative process [32].  
 
1.2. CELLULAR LOCALIZATION AND CELL SPECIFIC 
EXPRESSION  
The subcellular localization of CSTB and cathepsin B, H, and L in Cos-1, Saos-
2, L6 and neuroblastoma SHSY-5Y tissue culture cell lines has been studied by 
Riccio et al. [34] using confocal microscopy analysis. The authors show that, in 
proliferating cells, CSTB and cathepsins are concentrated in different cell 
  11compartments. In fact, CSTB is found mainly in the nucleus of proliferating 
cells and both in the nucleus and in the cytoplasm of differentiated cells. 
Cathepsins, in either case, are essentially cytoplasmic, localized in vesicles and 
structures associated with the surface of the cells. These results agree with the 
cytoplasmic localization of CSTB and cathepsins described by Calkins et al. 
[35] in two cell lines derived from murine hepatoma and embryonic liver. 
However, these authors do not observe nuclear localization of CSTB in the 
following cell lines: Morris hepatoma cells, primary rat oligodendrocytes and 
astrocytes, and two different rat and human neuroblastoma cell lines.  The 
distribution of Cystatin A and B in the cytoplasm of differentiated cells is 
diffused and most of the protein is not membrane bound, which is consistent 
with the absence of an N-terminal hydrophobic signal in the peptide sequence. 
CSTB is soluble and, although its sequence does not contain an obvious nuclear 
localization signal [34], the nuclear concentration of the protein in growing cells 
is higher than the cytoplasmic concentration. This may be due to a carrier that 
allows the translocation of cystatin into the nucleus or, alternatively, to the 
interaction of cystatin with a nuclear protein(s) or structure, which causes the 
retention of the anti-protease [36]. The cytoplasmic localization of cathepsin B 
is consistent with that found by other authors. Localization of the protein has 
been observed in vesicular structures, i.e., Golgi apparatus/lysosomes. It is 
interesting to note that Alakurtti et al. [37] have shown the presence of CSTB in 
the lysosomes of primary myoblasts.  
CSTB has also been described in extracellular fluids and in secretory granules of 
rat pancreatic endocrine B-cells [38-39]. 
 
Recently, Riccio et al. [40] have analyzed the pattern of expression of CSTB, in 
developing and adult rat cerebellum, using double immunofluorescence 
microscopy with specific cell markers (Figure 2). They have shown that, in 
  12primary glial cells, CSTB is found in progenitor and differentiated 
oligodendrocytes as well as in astrocytes. In the cerebellum, only 
oligodendrocyte progenitors express CSTB. In myelin-producing cells, CSTB 
synthesis is strongly down-regulated and the protein is not detectable. 
Astrocytes and Bergmann radial glia express CSTB at all the developmental 
stages analyzed, both in the cell body and in the fibers. Interestingly, terminally 
differentiated oligodendrocytes express CSTB in vitro whereas in vivo they do 
not. This observation is consistent with what has been described for 
differentiated cerebellar granule cells that express CSTB only in vitro [3]. The 
observed difference between CSTB expression in primary culture and cerebellar 
cells correlates with the reports made by Lalioti et al. [41] on EPM1 patients. In 
blood cells, CSTB is barely detectable whereas cultured blood and fibroblast 
cells from the same patients actively synthesize CSTB at a rate similar to that of 
normal individuals. The observed difference of CSTB expression in vivo and in 
vitro is consistent with the existence of a negative transcriptional control of the 
CSTB gene in some cell types. The down-regulation is abolished once the cells 
are cultivated in vitro [40].  
Most neurons of developing and adult rat cerebellum do not express detectable 
amounts of CSTB, with the exception of the Purkinje cells and of some cells of 
the differentiated molecular layer [40]. In human cerebellum, CSTB is present in 
Purkinje cells and Bergmann glial fibers only [40]. A specific role of CSTB in 
the Purkinje cells is in agreement with the cytochemical alterations observed in 
EPM1 patients and in the knock-out CSTB mice [1,42].  
CSTB is also found in the cortical neurons of the dentate gyrus of the hippocampus 
[40]. 
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  14Figure 2. Confocal analysis of CSTB expression in cells of the glial (A-U) and neuronal (A1-
L1) lineage. CSTB is red; the glial and neuronal markers are green. A–E: Double immuno-
fluorescence analysis of glial cell primary cultures. F–U and A1-N1: Double 
immunofluorescence of cryostatic sagittal sections of cerebella from 7, 13 and 90-day-old rats. 
Panels I, M, Q, U, D1, H1, and L1show a detail at three times magnification than in panels H, 
L, P, T, C1, G1, and K1, respectively. The arrows indicate: NG2+/CSTB
- cells in panel H; 
GFAP+/CSTB+ cells in panel P; CSTB+/NeuN
_ cells in panel G1; CSTB+/MAP2+ cells in 
panel K1. Scale bar, 50 Am. Markers: NG2 stains oligodendrocyte precursor cells. GFAP is an 
astrocyte marker. CNPase marks terminally differentiated oligodendrocytes. BLBP is expressed 
in radial glia throughout the development of the CNS. Calbindin in the cerebellum is present in 
the cytoplasm of Purkinje cells only. NeuN neuronal marker that binds to a poorly characterized 
nuclear antigen present in post mitotic granule but not Purkinje cells. MAP2 neuronal marker, 
present in Purkinje cells and in all neurons that have a highly developed dendritic and axonal 
structure. From Riccio et al. [40]. 
 
2. CYSTATIN B AND DISEASE 
2.1. MUTATION OF CSTB AND PROGRESSIVE 
MYOCLONUS EPILEPSY TYPE I  
The most studied pathology characterized by mutations of the CSTB gene is 
Progressive Myoclonus Epilepsy of the Unverricht-Lundborg type (EPM1) [9].  
EPM1 is a rare autosomal recessive disorder occurring mainly in Mediterranean 
and Baltic regions and in North America [43-44]. The clinical features of EPM1 
are severe cortical myoclonus, typically photosensitive, tonic-clonic or clonic-
tonic-clonic jerks and a neurologic deterioration that slowly leads to dementia, 
cerebellar ataxia and dysarthria [43,45-47]. Onset of syntoms occurs at 6-14 
years of age and severity is variable both between and within families [43-
45,48-49]. The benign course of the disease and the favourable response to 
antiepileptic drugs (i.e. valproate, piracetam, clonazepam, deazepam and 
zonisamide) allow patients to live to their 60s. Maybe this is the reason for EPM1 
being the most common progressive myoclonus epilepsy worldwide [50-51]. 
The interpretation of EPM1 patients’ histopathological data is confounded by 
the toxic effect of antiepileptic drugs (in particular phenytoin, which can be letal 
for EPM1 patients) and the degeneration of post-mortem specimens obtained at 
  15late stages of the disease [42,44,50,52]. Anyway, such analyses show non 
specific gliosis and neuronal degeneration without intracellular inclusions in 
many CNS areas [44,47,49-50,52-53]. Furthermore, cerebellar hemispheres (at a 
high degree) and most of the basis pontis and medulla undergo atrophy and 
cerebellum cortex is depleted of Purkinje cells [44,48-49,52]. The phenotype 
described for these cells is diverse, ranging from the presence of vacuoles or 
swollen axons, to shrinking and apoptosis of some of the cells [44]. The varying 
degrees of damage observed may be due to differences in the expression and/or 
function of CSTB within the Purkinje cell population observed by Riccio et al. 
[40].  
EPM1 is commonly associated with mutations in the CSTB gene (see Table 1). 
Most EPM1 patients carrying mutations in the CSTB gene are homozygous for 
the amplification of the dodecamer. The EPM1 heterozygous patients are always 
compound heterozygous for a dodecamer expansion and a point mutation 
[12,14,54-55]. Differently from other expansion diseases, EPM1 does not show 
anticipation [56-57]. 
Generally, EPM1 is associated with the loss of CSTB antiprotease activity, as a 
general inhibitor of proteolysis or as an inhibitor of caspases, either by direct 
interaction or by the inhibition of cathepsins that activate caspases. Anyway, 
there is no evidence of the direct interaction of cystatins either with caspases in 
vitro or in vivo, or with cathepsins in vivo. As cystatins and cathepsins are mostly 
localized in different cell compartments [35] it has been suggested that CSTB is 
involved in protecting cells against inappropriate cellular degradation by proteases 
that leak from lysosomes [63]. Alakurtti et al.  [37] have shown that CSTB 
EPM1 mutants Gln71Pro and Gly4Arg prevent the association with lysosomes.  
  16 
Table 1.    EPM1 MUTATIONS  
 
MUTATION  ALTERATION   HETEROZYGOSYS/HOMOZYGOSYS IN EPM1  REF. 
Transversion 1510 G → C  
in the last nt of INTRON 1  
invariant AG  → AC 




Transition 1938 A → G 
at the end of 
INTRON 2 
invariant AG → GG 
ABNORMAL SPLICING?  12 
Transition 1612 G → A 
in the last nt of EXON 2 
AAGLys56→AAA Lys56; EXON-INTRON 
JUNCTION ALTERATION  
→ ABNORMAL SPLICING? 
58 
Transition 1973 C → T 
in EXON 3 
CGAArg68→TGASTOP 
PROTEIN TRUNCATION AT Lys67 
(BEFORE THAN LOOP PH) 
9 
Deletion 1985 TC 
in EXON 3 
FRAMESHIFT FROM Ser72 AND 
STOP AT CODON 75 
→ PROTEIN TRUNCATION AT THE 
NEW Ser74 (WITHIN LOOP PH) 
12,55 
Transversion 1983 A → C  
in EXON 3 
CAAGln71→CCAPro71
  61 
Transition 1612 G → A 
in EXON 2 
GGGconservedGly50→GAGGlu50
 
REPRESENT ~ 14% OF EPM1 ALLELES (THE MOST 
FREQUENT IS THE 1510G → C) 
 
NO EPM1 PATIENTS HOMOZYGOUS FOR THESE ALLELES; 
THEY ARE ALWAYS IN COMPOUND HETEROZYGOUS 
FORM: 
POINT MUTATION/ DODECAMER EXPANSION  
 
PROBABLY THE HOMOZYGOSYS FOR THESE MUTATIONS 
CAUSES A DIFFERENT PHENOTYPE  
62 
Transversion G10→ C 




POINT MUTATION FOUND IN HETEROZYGOSYS WITH 
THE  DODECAMER EXPANSION AND IN 1 CASE IN 
HOMOZYGOSYS 
9,12 
EXPANSION OF THE  
DODECAMER (C4GC4GCG) 
in PROMOTER 5’UTR 
(C4GC4GCG)2-3 → (C4GC4GCG)30-75 
DOWN-EXPRESSION OF THE GENE IN SOME 
CELL TYPES, MAYBE CAUSED BY THE 
SEPARATION OF PROMOTER’S 
REGULATORY ELEMENTS 
REPRESENTS >85% OF EPM1 ALLELES 
 
IN >90% OF EPM1 PATIENTS THE DODECAMER IS EXPANDED IN 
BOTH ALLELES, BUT NOT NECESSARILY WITH THE SAME 
NUMBER OF REPETITIONS  
14,54,5
9-60 
 The authors suggest a lysosome-associated physiological function for CSTB that 
may contribute to the molecular pathogenesis of EPM1. Of all the natural 
mutants described, only the substitution at position 4 may alter the catalytic site 
of the molecule, although the cysteine at position 3 seems to be the most 
relevant in terms of interaction between cystatins and cysteine proteases [10,17]. 
Recently, Berkovic et al. [64] and Coppola et al. [65] have described EPM1 
cases in which the CSTB gene is not mutated and mutations of genes located on 
chromosomes others than 21 are the causative factors of the disease. The former 
authors [64] have studied an inbred Arab family with the clinical pattern of 
EPM1 and mapped the disease locus to the pericentromeric region of 
chromosome 12. This region currently contains known and predicted genes that 
have no obvious relationship to pathways involving CSTB biology. Thus, this 
study characterizes a novel pathway causing the EPM1 syndrome. 
 
2.1.1. THE ANIMAL MODEL 
Pennacchio et al. [66] have generated CSTB knockout mice with isogenic 129Sv and 
mixed 129Sv-C57BL/6 genetic background. The different genetic backgrounds 
produce different phenotypes. 129Sv-C57BL/6 CSTB-/- mice are not affected by 
myoclonus whereas the isogenic ones develop myoclonic seizures and progressive 
ataxia, though the EEG is not that characteristic of EPM1 [66].  
All mutant mice are smaller than w/t, suggesting a negative effect on the whole body, 
in agreement with the ubiquitous expression of CSTB [42,66]. As in EPM1 patients, 
morphological and histological alterations seem to be exclusive of the CNS and 
cerebellum, which is the most severely affected district [42]. CSTB deficiency 
damages both granule and Purkinje cells and leads to cerebellar atrophy. 
Furthermore, several areas of the hemispheres show neuronal atrophy and gliosis 
[42]. Based on the data of Riccio et al. [40], the apoptosis of granule cells observed 
in CSTB-/- mice could be secondary to the damage of Purkinje cells. 
  18CSTB knock out mice are used as model to unravel the etiology of EPM1 
disease and the physiological function of CSTB. Lieuallen et al. [67] have 
identified several genes that are differentially expressed in the brain of CSTB 
deficient mice compared to that of wt siblings. In particular, the protease 
cathepsin S was over-expressed. The authors have suggested that increased 
levels of cathepsin S in CSTB-deficient mice may be a key factor in initiating or 
propagating the apoptotic cascade. Houseweart et al. [68] have investigated the 
possibility that cathepsins initiate or propagate proapoptotic signals through the 
Bid signalling pathway. They crossed CSTB-deficient mice to Bid-deficient 
mice, and showed that cathepsins can promote apoptosis in the absence of Bid. 
The same authors [69] have also crossed CSTB-deficient mice with cathepsin B, 
L, and S-deficient mice. The removal of cathepsin S and L from the CSTB-
minus background did not rescue the EPM1-like phenotype of the CSTB-
deficient mice. The removal of the cathepsin B gene allowed for a partial rescue 
of the phenotype. Apoptosis was markedly reduced, whereas ataxia and 
myoclonus remained. These results suggest that the apoptosis of cerebellar 
granule cells observed in CSTB deficient mice is not due to the antiprotease 
activity of CSTB. The authors propose that other molecules besides cathepsin B 
are responsible for the pathogenesis. Recently, Kopitar-Jerala et al. [70] have 
investigated apoptosis triggered by the treatment of thymocytes with 
camptothecin, staurosporin and anti-CD95 antibodies. The thymocyte cultures 
were obtained from CSTB-deficient and wild-type mice. The treatment with 
inhibitors of calpain- and papain-like cathepsins does not prevent caspase 
activation. Based on these results, the authors conclude that apoptosis, induced 
by these agents in thymocytes, is not dependent on cathepsin inhibition by 
CSTB.  
The literature discussed so far does not univocally point to the absence of 
CSTB/prevalence of cathepsin(s) as the causative agent of the EPM1 disease. 
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involved in the etiopathogenesis of the disease [64-65], suggest that the situation 
is more complex than envisaged so far and puts forward the existence of 
additional causative factors unrelated to the cystatin/cathepsin pathway in the 
pathogenesis of EPM1. 
 
2.2. OVEREXPRESSION OF CYSTATINS. 
Cystatin A and B and cathepsins (in particular cathepsin L and B) have been 
implicated in the positive/negative progression of cancer, maybe due to the 
unbalance between the proteases and their inhibitors [70-77] and to cystatin 
involvement in cell growth. In particular, CSTB has been proposed as a 
prognostic marker in a number of tumours. Increased levels of CSTB are often 
associated to a decrease of relapse risk [11,71-79]. The only exception, so far 
described, is colorectal cancer where high levels of extracellular cysteine 
proteinase inhibitors indicate a poor prognosis [72]. 
 
CSTB is also involved in the defence of tissues against invasion by viruses and 
parasites and plays a role in the innate immune-response to bacterial challenge 
[80]. Following septic injury, CSTB is upregulated together with a number of 
other proteins [81]. CSTB expression is upregulated in monocytes upon their 
differentiation into macrophages [82], in macrophages exposed to LPS [83] and 
in airway epithelial cells after microbial or cytokine exposure [84]. 
CSTB and other cystatins share an additional role independent of their inhibitory 
activity: they upregulate nitric oxide release from interferon-γ-activated 
macrophages. Macrophages contain CSTB and secrete it into the cell culture 
medium [85] and when exposed to LPS they up regulate its expression [83]. 
Upon activation, macrophages acquire antimicrobial activities involving 
reactive-oxygen species and reactive-nitrogen metabolites and generate 
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 of NO in correlation with the concentration of cystatins in the 
culture medium. The saturation of the cystatin inhibitory site by papain does not 
interfere with the CSTB enhancing activity, showing that the active site of 
CSTB plays no part in this important physiological response [86].  
 
2.3. CYSTATINS AND AMYLOIDOSIS 
A variant form of cystatin C is the major constituent of amyloid plaques 
deposited in the brain of patients with hereditary cerebral amyloid angiopathy 
[87]. A Leu68Gln substitution is a mutation frequently found in patients affected 
by the icelandic type of amyloidosis [88].  Strong implications as to the 
mechanism of amyloidotic aggregation [89] came with the discovery that human 
cystatin C [90], human cystatin A [91] and human CSTB [29] have a propensity 
to form inactive dimers under pre-denaturing conditions and, moreover, that the 
L68Q variant of cystatin C partially dimerizes under physiological conditions 
[89]. It is not clear whether the molecular basis of this pathology depends on the 
anti-protease activity of cystatin C.  
The presence of cystatins in amyloid plaques of patients suffering from 
neurodegenerative diseases has also been described. Both cathepsins and 
cystatins are found in close association with senile plaques, cerebrovascular 
amyloid deposits, and neurofibrillary tangles in Alzheimer's disease (AD) [92-
93]. Furthermore, profound changes in the lysosomal system seem to be an early 
event in "at-risk" neurons of AD patients. Whether or not lysosome-associated 
proteolytic mechanisms are causally related to the development and/or further 
progression of the disease [94] remains controversial. Recently, wild-type 
Cystatin C has been found as a component of amyloid plaques in Alzheimer’s 
disease [95] and a polymorphism in the cystatin C gene has been linked to late-
onset Alzheimer’s disease [96-97]. Increased cystatin A and B in the senile 
plaques of Alzheimer's and Parkinson's, and of patients suffering from senile 
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[98]. It would be interesting to uncover the structure of these molecules in the 
context of the amyloid plaques and whether they exist in a polymeric form.  
Increasing evidence suggests that cystatins not only have a high degree of 
similarity both in their amino-acid sequence and in their three-dimensional 
structure
 [99-100], but also share a common propensity to form small oligomers 
[101-102] and fibrils [103-105] in vitro. As CSTB is a simple globular protein 
without disulfide bonds and forms amyloid fibrils under mildly acid conditions 
[104], it is used as a representative model protein for studies of the mechanism 
of amyloid-fibril formation. 
 
2.3.1. CSTB, A MODEL OF AMYLOID FIBRIL GENERATION IN VITRO 
Recombinant human CSTB is a useful model system for amyloidogenesis
 
[103,106]. Fibrillation in vitro is induced by the destabilization of the native 
state of proteins maintaining conditions that favor secondary structure formation 
[107]. Fibrillation of CSTB is promoted by a variety of experimental conditions 
(and by their combination): acidic solvents (pH3-5), high temperature (up to 
65°C), presence of trifluoroethanol (TFE) (10-20%) or high ionic strength (>0.1 
M NaCl) [107]. As observed for other proteins [108], within 1-3 weeks, 
amorphous aggregates are formed followed by the appearance of fibrillar species 
on the boundaries of amorphous clumps while, at later stages (1-3 months), the 
ordered aggregates predominate (Figure 3) [107]. This has led to the proposal 
that amorphous aggregates may be the source of nucleation sites for amyloid 
formation [109].  
Local concentration of the protein and its external environment determine different 
morphology of deposited amyloid fibres [107]. Morphological heterogeneity is 
characteristic of aggregates generated by different amyloidogenic proteins [108-
115].  
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Figure 3. Amorphous aggregation. A: electron micrographs of the large amorphous 
aggregates occurring within an hour of triggering the reaction at pH 4.8, 10% TFE and 37
oC. 
The scale bar represents 0.5μm. With time, small fibrillar species appear at the edges of the 
aggregates (B) and eventually mature fibres predominate on the EM grids (C). From Zerovnik 
et al. [107]. 
 
2.3.2. 3D-DOMAIN SWAPPING OF CYSTATINS IN VITRO 
Cystatins represent a unique example of a set of proteins in which small 
oligomeric assemblies can be observed and isolated on the pathway to amyloid 
fibrils. Among cystatins, CSTB is the most suitable model for studying the 
kinetics and morphology of amyloid-fibrils whereas cystatin A and cystatin C 
are useful systems to decipher the early steps in the aggregation reaction [116]. 
In vitro, cystatins form highly stable domain-swapped dimers at physiological 
protein concentrations [2,102-103,117-125]. In 3D domain swapping, two (or 
more) subunits exchange identical structural elements or “domains” leading to 
the recreation of the monomeric fold in an aberrant way, from chain segments 
contributed by different subunits. In a protein capable of domain swapping, 
there must exist a flexible linker or hinge whose conformational changes allow 
the molecule to adopt different folds [74].  
In cystatin swapped dimers loop 1 of each monomer is the hinge that opens and 
becomes part of a long β-ribbon running from the beginning of strand β2 to the 
end of strand β3. It leads to the creation of an unusually long contiguous 
antiparallel  β-sheet formed by two copies of the β2-loop1-β3 ribbon, which 
cross from one domain to the other [2,120,123-125].  
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of amyloid deposits, the domain-swapped dimer of chicken cystatin further 
oligomerizes to a tetramer, before fibrillization. In contrast with other domain 
swapping proteins such as CD2 [190] or RNase A [191-197], no trimeric or 
pentameric species are detectable, suggesting that the chicken cystatin assembly 
competent species is the dimer rather than the monomer. The tetramer reverts to 





Figure 4. Crystal structure of CSTB tetramer. (a) Ribbon representation of the tetramer of 
CSTB. The tetramer is build of two domain-swapped dimers related by the crystallographic 2-
fold axis (black ellipsoid). The upper  domain-swapped dimer is composed of yellow and 
green chains, whereas the lower dimer is composed of red and blue  chains. The upper 
and lower dimers are intertwined by the S72-L80 loop regions. Between the swapped domains 
there are linker peptides comprising residues from V47 to G50. (b) The upper dimer(yellow 
chain) swaps the S72–L80 loop with the lower dimer (red chain) and forms a tetramer. The 
hand shake is possible due to a trans/cis proline isomerization of the P74 residue. As a result, 
the H75 side-chains are packed together in an antiparallel arrangement. From Kokalj et al. [126]
 
Recently Kokalj et al. [126] determined both the crystal and NMR structures of 
human CSTB C3S tetrameric species (Figure 4). The crystal structure reveals 
that the tetramerization of CSTB, and possibly of other cystatins, is not a further 
domain swapping event as initially proposed by Sanders et al.[122]. In fact, the 
process involves a related mechanism, that the authors term “hand shaking”, 
  24through which 3D domain-swapped dimers become entwined. The hand shaking 
reaction is dependent on the trans to cis isomerization of Pro74, the only proline 
residue that is widely conserved throughout the cystatin super family (it is the 
Pro of the consensus PH of loop 2). The most pronounced effect of P74 
isomerization is the difference in the position of the H75 side-chain. In the 
monomeric and dimeric forms, it points inside its own loop 2. In contrast, in the 
tetrameric form, the four H75 point away from their loop 2 and are directed 
towards the corresponding loop 2 of the neighbouring dimer. The result is that 
each dimer swaps its two loops 2 with those of the other dimer generating the 
tetramer [126]. 
 
3. CYSTATIN B INTERACTORS 
The physiological role of CSTB is unclear. The apparent contradiction between 
the known role of the ubiquitous CSTB antiprotease and the specificity of the 
district affected by EPM1 disease suggests that in the CNS it plays a specific 
and essential function protecting the cells against apoptosis [9, 66]. As such a 
specific function could be correlated to the interaction of CSTB with proteins 
exclusively expressed in the CNS, Di Giaimo et al. [3] have used the two hybrid 
system technique to isolate partners of CSTB expressed in rat cerebellum. 
Interestingly they did not find any proatease among the interacting proteins. The 
absence of proteases among the identified proteins may be explained if one takes 
into account the weak interaction between CSTB and cathepsin B observed in 
yeast and in vitro, and/or a fast exchange rate of the antiprotease-protease 
binding. Among the identified CSTB partners, several are cytoplasmic proteins 
involved in the regulation of cytoskeletal functions. Di Giaimo et al. [3] have 
characterized five of these peptides: brain β-spectrin, NF-L, RACK-1, TCrp and 
Mtrp. At least β-spectrin and NFL are expressed exclusively in cells of the 
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five interactors bind CSTB in the GST pull-down assay and that the interaction 
occurs with the GST–CSTB exon II and GST– CSTB exon III fusion peptides [3].  
Di Giaimo et al. [3] have further confirmed the interaction between CSTB and 
NFL,  β-spectrin and RACK-1, in vivo, by experiments of co-
immunoprecipitation of rat cerebellar protein extracts. The interaction of NF-L, 
β-spectrin and RACK-1 with CSTB is detectable in the cerebellum and not in 
the brain hemispheres, indicating the tissue specificity of the protein complex [3].  
Based on these results Di Giaimo et al. [3] have hypothesized the existence of 
one or more possible specific roles of CSTB, mediated by its interaction with 
different partners either in the nucleus or in the cytoplasm. In particular, they 
have proposed that CSTB in the cerebellum is part of a specific complex of 
unknown function. The disruption of this complex in EPM1 patients may be the 
cause of the disease. It may be worth underlining that the region of chromosome 
12 identified by Berkovic et al. [64] as the site of an EPM1 natural mutant is 
rich in structural and cytoskeletal genes. 
In the cerebellum β-spectrin, NF-L, RACK-1 are co-expressed and co-localize 
with CSTB in different cells depending on the age of the animal: during 
development in the granule cells, and in the adult in the Purkinje cells and 
maybe in the Bergmann glia as well (Figure 5) [3,40].  This observation is 
consistent with the results of Pennacchio et al. [58] who show the loss of granule 
cells in the cerebellum of CSTB knock-out mice. The latter finding correlates 
with the marked loss of Purkinje cells revealed by autopsy of patients affected 
by EPM1 [44,127].  
The multiprotein complex identified by Di Giaimo et al. [3] contains at least 
CSTB, NF-L, β-spectrin and RACK-1, but may also contain further peptides, 
which may not interact directly with CSTB. The size of the five proteins 
interacting with CSTB varies from approximately 30 to more than 200 kDa and  
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Figure 5. Double immunofluorescence analysis of cryostatic sagittal sections of cerebellum 
from 7, 13 and 90-day-old rats. CSTB is red. RACK-1 (B, D, F), β-spectrin (H, J, L), and 
NFL (N, P, R) are green. On the right of each image, the co-localization of the signals is 
shown in white. Scale bar, 50 Am. From Riccio et al. [40]. 
 
CSTB is a small protein of approximately 12 kDa. It seems therefore unlikely 
that all these proteins interact directly with CSTB at once, unless CSTB is in a 
dimeric or polymeric form [3]. However, RACK-1, NF-L and β-spectrin have 
multiple interaction domains and may interact in different sites with one another 
as well as with CSTB. 
 
The RACK-1 receptor (Receptor for Activated C-Kinase 1) is a scaffolding 
protein of 36 kDa and belongs to the family of WD40 repeat proteins [128]. Its 
seven WD40 protein interaction domains make RACK1 especially versatile. In 
fact, it specifically binds several proteins and can simultaneously contact more 
than one protein. For this reason RACK1 is involved in a variety of signalling 
pathways. The receptor’s main function is to translocate to the cell membrane 
some of the activated isoforms of PKC [129]. The three C-terminal WD 
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phosphatase proteins [130-133].In conditions that promote cell spreading and 
adhesion, RACK1 directly and specifically interacts with the cytoplasmic 
domains of IGF-1R [134-135] and integrin-β [136], being thus implicated in 
their signalling pathways and in the contacts between plasma membrane and 
cytoskeleton [137]. It is abundant during cell proliferation and differentiation 
[138-139] and it is induced during angiogenesis, including that of tumours 
[140]. In the CNS RACK1 is involved in the neurite outgrowth in retinal 
ganglion cells [141] and Yaka et al. [142] have demonstrated that, in the CA1 
hippocampal region, RACK1 decreases NMDA receptor activity binding the 
NR2B subunit of the NMDA receptor and the protein-tyrosine kinase Fyn that 
phosphorilates the NR2B subunit. 
 
NF-L (Neurofilament Light chain) is the 68 kDa subunit of the structural core of 
neurofilaments, the most abundant intermediate filaments (IF) in neurons of the 
central and peripheral nervous systems. NF-L conforms to a tripartite structure 
consisting of a highly conserved a-helical rod domain flanked by variable non-a-
helical N- and C-terminal domains (“head” and “tail”, respectively), responsible 
for specific functions [143-145]. In neurons, NFL plays important roles in the 
growth, maintenance and regeneration of large myelinated axons [146]. 
Furthermore, it is involved in neuronal differentiation including migration, 
neurite outgrowth, target recognition, and synaptogenesis [147]. In mammalian 
neurons, NF-L may target the functions of protein phosphatase-1 in membranes 
and cytoskeleton [148]. In the dendrites and growth cones of cultured 
hippocampal neurons, NF-L directly interacts with the NR1a subunit of NMDA 
receptor [149]. NF-L mutations are correlated to Charcot-Marie-Tooth disease 
type 2, a severe hereditary motor and sensory neuropathy [150-154]. 
Furthermore, its down-expression is associated with ageing [155-156] and 
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amyotrophic lateral sclerosis (ALS) [157-163]. Parkinson’s disease and ALS are 
characterized by neurofilamentous accumulations (Lewy bodies and spheroids, 
respectively) and anomalies in NFL expression, distribution and/or 
phosphorylation. The cytoplasmic accumulations may be toxic or represent a 
residual regenerative activity or an aspecific response to axonal or neuronal 
damage. 
 
β-spectrin (about 240 kDa) is one of the two subunits of spectrin, a giant, 
extended and flexible molecule in which two antiparallel elongated α-β 
heterodimers are associated head-to-head to generate a tetrameric filament of 
about 200 nm [164-168]. All spectrin subunits share the same structural 
organization. The central portion of the molecule contains 17-30 repeats, the 
“spectrin repeats” that characterize the family and are organized in three α-
helices (A, B, C) connected by two β-turns [164, 166, 169-170]. The N- and C-
terminal regions are highly variable and comprise protein-protein interaction 
domains [168]. The modular structure is probably at the basis of the implication 
of spectrins in a variety of physiological processes. In fact, it combines 
numerous protein-protein interaction domains in several different isoforms, 
differentially expressed and localized according to organs, developmental 
stages, cell populations or sub-populations and cell compartments [168, 171]. 
Spectrin is the major component of the membrane skeleton. It associates to the 
cell membrane directly, interacting with membrane proteins, or indirectly, 
binding membrane attachment proteins such as ankyrins and protein 4.1. 
Spectrin also binds Ca2+ and calmodulin, which regulate its binding to the 
membrane [198]. Spectrins crosslink actin filaments into an isotropic meshwork 
underlying cellular shape and asymmetry, membrane stability and deformability, 
as well as the formation of membrane subdomains [167, 172-176]. Spectrins are 
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sorting, vesicle trafficking and formation/maintenance of nucleus shape [177-
182]. In neurons, spectrin is implicated in neurite outgrowth and in the 
topographical organization of groups of receptors or of cytoplasmic multiprotein 
complexes, in specialized domains [182-185]. 
β-spectrin interacts with the rod domain of NFL [186]. The binding requires at 
least an other protein, still unknown, that connects the two proteins and 
modulates their association [187]. In vitro a single β-spectrin molecule can bind 
up to 60 NFL molecules [188]. 
Rodriguez et al. [189] have shown that β-spectrin interacts with RACK1 as well. 
In this case, the interaction is direct and independent from the binding between 
RACK1 and PKCβ. 
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1. INTERACTION OF CYSTATIN B WITH 
CYTOPLASMIC PROTEINS 
1.1. CSTB INTERACTORS 
Cell proteins are compartmentalized and can interact only if they are in the same 
sub-cellular district. The analysis of protein interactions with purified proteins, 
in in vitro systems, indicates the possibility of their interaction but does not 
guarantee that the binding takes place in vivo. In order to confirm and expand 
the analysis of CSTB interactors initiated by Di Giaimo et al. [3] with the two 
hybrid and the GST-pull down techniques, we have analysed the proteins that 
interact with CSTB, directly or indirectly, in a (neuronal) mammalian cell line. 
We have chosen the 293T cells as model system because they have an expression 
phenotype surprisingly similar to early differentiating neurons and to well defined 
cell lines of the neuronal lineage (PC12 and Ntera-2 cells) [199]. These cells are 
easy to colture and, in contrast with other neuronal cell lines, easy to transfect. As 
commercial anti-CSTB abs are not efficient in immunoprecipitation experiments, 
we have immunoprecipitated HA-CSTB from 293T cells transfected with the 
pRK7-HA-CSTB vector. The immunoprecipitated proteins were separated by 
2D-PAGE (Figure 6).  
The gel contains spots of a MW ranging from 12 to more than 200 kDa. The 
isoelectric point is within pH 3 to 10. This suggests that, in agreement with Di 
Giaimo et al. [3], CSTB interacts with many proteins generating different 
multiprotein complexes. The indicated spots were analysed by mass 
spectrometry. They correspond to proteins involved in vesicle traffic, 
cytoskeletal modelling and calcium metabolism, i.e. annexin A2 and 11, 
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phosphate dehydrogenase (GAPDH), enolase and trioso-phosphate isomerase. 
The intense spot at the bottom of the gel with a pI of about 7.5 is HA-CSTB. 
The nature of the CSTB partners points to a cytoskeletal function. Furthermore, 
our results suggest a role of CSTB in Ca2+ signalling at the membrane level. It 






Figure 6. 2D gel electrophoresis of CSTB interactors. Immunoprecipitate with anti HA(F-7) 
abs from 293T cell protein extract. The indicated spots, stained with silver, were analysed by 
mass spectrometry and the corresponding proteins were identified. 
 
  321.2. INTERACTION OF CSTB AND EPM1 MUTANTS WITH 
RACK1, NFL AND β-SPECTRIN  
If the alteration of the multiprotein complex described by Di Giaimo et al. [3] 
plays a role in EPM1 etiology, it is possible that one or more of the EPM1 
mutants fail to interact with the CSTB partners. Our working hypothesis is that a 
stable mutant, when over-expressed, acts as a negative dominant. In order to 
analyse the binding of CSTB and its mutants in vivo, we have chosen a cell line 
where RACK1, NFL and β-spectrin are expressed. The western blot analysis of 
a 293T cell extract stained with anti-CSTB, anti-RACK1, anti-NFL and anti-β 
spectrin abs, shows that the four proteins are detectable in these cells (Figure 7A).  
Panels B-D show the results of the imunoprecipitation of protein extracts from 
293T cells transfected with wt, G4R, Δ68 CSTB (lanes 1-3) and non transfected 
cells. The abs used for the immunoprecipitation were anti-β spectrin (B), anti-
NFL (C) and anti-RACK1 (D). The immunoprecipitated proteins were separated 
on SDS-PAGE and the western blots were stained with anti-HA abs. Panels B 
and C show that the WT and G4R immunoprecipitates have a very similar 
pattern of bands, mainly in the regions corresponding to the MW of CSTB 
monomer and dimer. Fainter bands of higher MW are also detectable. The Δ68 
deletion mutant, which is missing 30 amino acids at the C-terminus, shows 
faster running bands, both in the low and high MW range. These results show 
that NFL and β-spectrin interact with wt CSTB and EPM1 mutants, indicating 
that neither the catalytic site nor the C-terminus of CSTB are involved in this 
interaction. Panel D analyses the interaction of RACK1 with CSTB. The 
banding pattern is similar for the WT and G4R samples, indicating interaction 
between the proteins. In contrast, RACK1 does not immunoprecipitate Δ68 
CSTB as the only detectable band corresponds to IgM. We conclude that 
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Figure 7. Western blot of immunoprecipitated CSTB and EPM1 mutants. A: Protein 
extracts from 293T cells stained as indicated. B-D: Immunoprecipitation of protein 
extracts from 293T cells, transfected and non transfected (NT) as indicated.  
 
 
  342. CYSTATIN B IS POLYMERIC IN VIVO 
2.1. CELLULAR CSTB HAS A POLYMERIC STRUCTURE 
The western blots in figure 7 show, in addition to monomeric CSTB, bands of 
MW higher than expected, corresponding to the position of dimers and larger 
components. Thus, we have decided to examine the structural organization of 
endogenous CSTB in a series of cell lines (293T, SAOS, HeLa and SKNBE 
cells). Figure 8 shows a western blot analysis of protein extracts from cells lyzed 
under different conditions and electrophoresed in absence or presence of 50 mM 
DTT. The expected MW for CSTB is approximately 12 kDa. In the absence of 
DTT, a complex pattern of bands ranging between 10 and 250 kDa is present in 
all lysates with a similar distribution. The reducing condition increases the 
intensity of the 12 kDa band although some of the polymers are still detectable. 
It should be noticed that the CSTB pattern is similar in all samples, independent 





Figure8. Western blot analysis of CSTB in human cell lines. SDS-PAGE of protein extracts 
lyzed under non denaturing conditions (buffer 1: lanes 1 and 3), denaturing conditions (buffer 
2 containing 1%SDS: lane2) or lyzed directly in protein loading buffer (lanes 4-9). Staining 
with anti-CSTB abs. 
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background, we have checked the antibody specificity by preabsorption 
experiments. Figure 9A shows that preabsorption of the anti-CSTB abs with 
human CSTB, synthesised in E. coli, erases the endogenous signal. The same is 
true in B, were the 293T cells were transfected with rat HA-CSTB and 
preabsorption was carried out with rat HA-CSTB synthesised in E. coli. The 
results of these experiments show that CSTB, in vivo, has a polymeric structure 
which is resistant to SDS denaturation (Figure 8: lanes 2, 4-9) and partially 
sensitive to DTT treatment (Figure 8: lanes 3, 5, 7, 9). The observed SDS 
resistance suggests the existence of covalent bonds responsible for the high MW 








Figure 9. Abs specificity. SDS-PAGE and western blot analysis. A: Protein extract from cells 
lyzed in buffer 1. Staining with anti-CSTB abs: untreated (lane 1), preabsorbed with E. coli 
protein extract expressing human CSTB (lane 2) or E. coli protein extract (lane 3). Lower 
panel: staining with anti-GAPDH abs. B: Protein extract from 293T cells transfected with the 
pRK7-HA vector containing rat CSTB cDNA lyzed in buffer 2. Staining with anti-HA(F-7) 
abs: untreated (lane 1), preabsorbed with E. coli protein extract expressing rat HA-CSTB 
(lane 2) or E. coli protein extract (lane 3). 
 
  36A treatment with 8 M urea does not denature CSTB polymers (Figure 10), 
although a few bands, in the intermediate MW region of the gel, are no longer 
detectable. We conclude that the polymeric structure of CSTB is resistant to 





Figure 10. SDS-PAGE and western blot analysis of the same protein extracts as in figure 9B 
incubated 1 Hr as indicated. No reducing agents added. Staining with anti-HA(F-7) abs. 
 
We have analysed native CSTB by size fractionation on a Superdex 75 column 
(Figure 11). The MW range for optimal separation with this column is 3-70 kDa. 
Fractions 17-18 contain the excluded peak of the column and from fraction 19 
onward the separation starts (see material and methods). The size distribution of 
proteins stained with Poinceau red shows the expected separation of the MW in 
fractions 19-30 (panel A). Immunostaining of the filters with anti-CSTB abs 
shows that low MW components, mainly monomers, are in fractions 21-30 
(panel B). Fractions 27-30 correspond to the approximate MW of CSTB 
monomer, dimer and trimer suggesting that a small amount of CSTB is not 
bound to other proteins. Monomeric CSTB in fractions 21-26 is probably 
released from its interaction with cellular proteins of increasing MW upon SDS 
boiling and SDS PAGE. In fact, native CSTB interacts with a number of 
proteins that increase its size on fractionation 
 (Di Giaimo et al., 2002; Figures 
  376-7 ). Polymeric CSTB is detectable in fractions 17-20 that include the excluded 
peak and its position may indicate again interaction with other proteins. The 
separation between low and high molecular mass components shows that 
polymerization of CSTB is not an artefact due to SDS or self-assembly.  
 
A       
 
B       
 
 
Figure 11. SDS-free size exclusion chromatography of CSTB from a native protein extract of 
293T cells analysed on a Tricorn Superdex®75 column: Fractions from the column loaded on 
SDS Laemmli gel without reducing agents and analysed by western blot. A: Staining with 
Poinceau red. B: Staining with anti-CSTB abs. 
  382.2. CSTB FORMS HOMOPOLYMERS 
To clarify the nature of the SDS resistant proteins, the CSTB polymers were 
analysed by in gel digestion and mass spectrometry, following lysis in buffer 2 
(Figure 12). Protein extracts from human 293T cells, transfected with the rat 
HA-CSTB construct, were immunoprecipitated with anti-HA abs, and 
electrophoresed on SDS-PAGE. The bands indicated in A were analysed and the 
experimental results were compared to the theoretical molecular mass values 
(panel B). Bands 1, 2, 3 migrate at the position of endogenous and transfected 
monomers. Bands 4 and 5 migrate as homo- and hetero-trimers and band 6 as a 
pentamer. Protein modifications are not detectable although monomer, dimer 
and trimer migrate in multiple bands within the range of approximately 2 kDa. 
We envisage two possible reasons for this: 1. The N-terminal region of the 
protein (fragment 1-24) was not identified by mass spectrometric analysis, 
therefore the presence of modifications within the first 24 aminoacids can not be 
excluded. 2. The structure of the protein is unstable and shows conformational 
differences [2]. The identity between the experimental and theoretical molecular 
mass values confirms that the bands contain CSTB only, and that their position 
in the denaturing gel is not due to the interaction with other proteins. As we have 
transfected human 293T cells with rat CSTB and the rat and human sequences 
are different, we can distinguish the endogenous human from the transfected rat 
molecules (panel B and Figure 16). Accordingly, the peptide analysis shows the 
presence of a mixture between human and rat CSTB. Both species are present in 
polymeric and monomeric forms. The presence of heteropolymers is explained 
by the interaction between endogenous and transfected CSTB. The presence of 
the human CSTB monomer may reflect the formation and partial denaturation of 
heteropolymeric CSTB following boiling. We conclude that SDS resistant 
CSTB polymers are not due to covalent interaction with proteins different from 
itself and that CSTB forms highly stable homopolymeric structures. 







Figure 12. Mass spectrometry analysis of CSTB polymers. A: Immunoprecipitation with anti 
HA(F-7) abs from the same protein extract as in figure 9B. No reducing agents added to the 
sample. Gel stained with colloidal brilliant blue G (Sigma). Numbers on the right indicate the 
analysed bands. B: Mass spectrometry analysis. The position of each peptide within the CSTB 
sequence is shown. H refers to human and R to rat CSTB.  
 
2.3. CSTB POLYMERS ARE SENSITIVE TO THE REDOX 
ENVIRONMENT 
Figure 13 analyses the properties of polymers in relation to a treatment with 
reducing agents. The effect of increasing pH on the structure is shown in panel 
A where polymers are barely detectable at pH 9.8. Glutathione at a 
concentration 2.5-20 mM decreases but does not eliminate the high MW CSTB 
bands (panel B). The effect of these treatments suggests that CSTB polymers are 
somewhat resistant to denaturation and that a combination of reducing and 
denaturing conditions are necessary to depolymerise most of the protein. 
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Figure 13. Effect of pH and GSH on CSTB polymers from the same protein extract as in 
figure 11. No reducing agents added to the samples. Staining with anti-CSTB abs. Lower 
panels: staining with anti-GAPDH abs. A: pH curve as indicated. B: Samples treated with 
increasing concentrations of GSH as indicated.  
 
 
Figure 14 shows the effect of H2O2 addition to a protein extract from 293T cells. 
As the concentration of H2O2 increases, first we observe an increase of the dimer 
band, followed by the trimer that becomes the dominant species starting from 1 
M H2O2 (B-D). This result suggests that, under oxydising conditions, the 
trimeric structure of CSTB is very stable. Under reducing conditions (D) 
monomers are released from the high MW components up to a concentration of 
0.8 M H2O2. The sample treated with 1.0 M H2O2 shows considerable resistance 
to denaturation of the trimer and of some higher MW components suggesting the 
existence of irreversible hyperoxydated species, carrying sulphonylated, 
carbonylated or nitrated residues [200-201].  











Figure 14. Effect of H2O2 on CSTB polymers from the same protein extract as in 
figure 11. Samples treated 10 min at RT with increasing concentrations of H2O2 as 
indicated, 0* non incubated sample. Staining with anti-CSTB abs. Lower panel in 
A: staining with anti-GAPDH abs. In C, the dotted line indicates the position of the 
stacking region of the gel. A-C: No reducing agents added to the samples. D: Lanes 
1-4: minus reducing agents, lanes 5-8: plus reducing agents. 
 
3. CYSTATIN B MUTANTS ARE POLYMERIC 
3.1. THE CYSTEINE MINUS MUTANTS 
The reactive thiol groups fulfil a sensory and regulatory role on proteins, in 
response to a defined redox environment. A highly conserved residue of CSTB 
is the cysteine at position 3. Most CSTB, including the human molecule, contain 
only this cysteine, while rodent CSTB has an additional cysteine at position 64.  
 






Figure 15. Transfection of CSTB mutants in 293T cells lyzed in buffer 2. 
Immunoprecipitation with anti-HA(F-7) abs of protein extracts from 293T cells transfected 
with wt and mutant constructs indicated under the lanes. NT refers to non-transfected cells. 
SDS polyacrylamide gels run minus (A) and plus (B) 200 mM DTT. Staining with anti-
HA(Y11) abs. The dotted line indicates the position of the stacking region of the gel. 
 
Since both human and rat cells contain polymeric CSTB, disulphur bonds can 
not be responsible for their formation. However the phylogenetic conservation 
of Cys3 and the sensitivity of the high MW species to the redox environment 
suggest that at least one cysteine is important. Thus, we have analysed the 
structure of single and double cysteine substitution mutants of rat CSTB. The 
immunoprecipitates from protein extracts of cells transfected with these 
constructs are in figure 15. The banding pattern of the single substitution 
mutants is similar to that of the wt protein suggesting that the two cysteines 
present in the rat molecule are interchangeable. In contrast, the ΔCys mutant 
shows mainly monomers and dimers in addition to high MW polymers stacked 
in the high portion of the gel. The middle MW components are not detectable. 
The addition of 200 mM DTT (B) to C3S, C64S and wt CSTB decreases the 
amount of protein in the stacking gel and releases components migrating in the 
middle MW range. The ΔCys mutant does not respond to DTT addition. We can 
conclude that disulphur bonds are not necessary to form dimers, and that neither 
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of high MW species. However, reactive thiol groups seem to be important to 
stabilize the intermediate MW species which are clearly visible and stable when 
at least one cysteine is present in the sequence. Cystatin dimers generated in 
vitro by domain swapping have been described by Staniforth et al. [2] as the 
initial step to the formation of amyloid fibers. It is possible that the dimer that 
we observe in vivo has a similar origin implicating hydrophobic interactions. 
However, the existence of different types of covalent bonds can not be excluded.  
 
3.2. THE DISEASE MUTANTS  
We have analysed the structural organization of a number of CSTB mutants 
including those isolated from EPM1 patients (Figure 16). The following natural 
mutants were constructed: G4R, Q71P, Δ68 and Δtc. Laboratory mutants were 
constructed using the cystatin sequence alignments published by [202]: Δ64 
(stop codon at position 64), ΔΕ1(deletion of exon 1 encoding aminoacids 1-22), 
the substitution mutants V59Q and T87K. The latter substitutions are derived 
from the cystatin C mutants I66Q and I102K described by Staniforth et al [2]. 
I66Q is the chicken equivalent of human L68Q, from patients affected by the 
Icelandic type of amyloidosis [203]. Staniforth et al [2] have shown that the 
I66Q mutant forms essentially dimers while the I102K generates monomers only.  
All CSTB mutants generate high MW structures (Figure 17A). Differences in 
the banding patterns are mainly due to the different MW of the constructs. In 
agreement with the previous experiments, the addition of 200 mM DTT is not 
sufficient to depolymerize CSTB completely (panel B). Both carboxyl- and 
amino-terminus deletion mutants seem to polymerize very efficiently. In 
contrast to the results obtained by Staniforth et al. [2] in vitro, the V59Q and 
T87K generate monomers and high MW components, suggesting that there is a 
difference between the in vivo and in vitro process of polymerization. We 
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Figure 16. Structure of wt and mutant rat CSTB constructs. The vertical lines in the wt 
scheme indicate the position of amino acids which differ between rat and man. The asterisks 
indicate the position of the amino acid substitutions in the mutants. The dotted lines indicate 
the position of the phylogenetically conserved motives shown above. 
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  463.3. THE LOOP 1 MUTANTS  
According to Staniforth et al [2], aminoacid substitutions in the QVVAG loop of 
cystatins do not allow polymerization of the molecule. We have generated single 
and double substitution mutants of this region to see whether in vivo 
polymerization requires the integrity of loop I. The mutant V48D corresponds to 
the chicken mutant V55D of Staniforth et al [2]. We have also generated 
additional mutations at the most highly conserved sites of the QVVAG loop: 
V48A, G50A and VG48/50A. The substitutions at aminoacid positions 48 and 
50 were also inserted in the cysteine minus constructs (ΔCys/V48A and 
ΔCys/G50A). The distribution of the CSTB bands in all mutants is similar to 
that of the wt protein with the exception of the cysteine minus constructs that 
show monomers, dimers and bands larger than 250 kDa as dominant species, 





Figure 18. Western blot analysis of protein extracts from 293T cells transfected with single 
and multiple substitution mutants of loop 1. Cells lyzed in buffer 2. No reducing agents added 
to the samples. Staining with anti-HA(F-7) abs. The dotted indicates the position of the 
stacking region of the gel. 
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capacity of CSTB in vivo, irrespective of the presence/absence of cysteines in 
the molecule. These results are in contrast with those obtained by Staniforth et al 
[2] in vitro. This difference may be due to the presence of chaperon or other 
proteins involved in the in vivo polymerization [204].  
 
4. MOLECULAR MECHANISM OF 
CYSTATIN B POLYMERIZATION 
4.1. CSTB POLYMERS IN PROKARYOTIC CELLS 
The experiments described so far show that eukaryotic cells polymerize CSTB 
and that the polymeric structure is sensitive to reducing and oxydising agents. It 
is possible that 1) the redox environment regulates the reaction and 2) the 
reaction is mediated by a factor, possibly an enzyme. While expressing wt 
CSTB in E. coli, we have observed that the protein has a polymeric structure 
undistinguishable from that found in the mammalian 293T cells. Figure 19A 
shows the SDS−PAGE of protein extracts from E. coli cells transformed (lanes 
1, 3) and 293T cells transfected (lanes 2, 4) with expression vectors empty or 
plus wt CSTB cDNA. Panel B shows the SDS-PAGE of wt and mutant HA-
CSTB constructs expressed in E. coli. The banding pattern observed in the 
wt protein is also present in all the mutants with the exception of the proteins in 
which both cysteines were substituted by either alanine or serine. The pattern of 
the latter mutants differs from the others mainly for the paucity of bands in the 
middle MW range, between approximately 25 and 250 kDa. Interestingly, this 
pattern is the same as that observed in transfected 293T cells (Figure 17). We 
can conclude that the polymerizing activity found in 293T cells is present also in 
the E. coli prokaryotic system. 
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Figure 19. Expression of CSTB. Western blot analysis of total protein extracts. The 
staining was with anti−HA abs, no DTT added. A. protein extracts from 293T cells 
transfected (lane 1) and non transfected (lane 3) and E. coli cells transformed (lane 2) and 
non transformed with the HA-CSTB expression vectors. B. Protein extracts from E. coli 
cells transformed with wt and mutant HA-CSTB vectors, and with the empty vector (E). 
 
Figure 20 shows the western blot of a 2D-PAGE of HA-CSTB 
immunoprecipitated from an E. coli protein extract. The anti-HA immunoblot 
allows the identification of a variety of spots (panel A). According with the 
results obtained with mammalian cells, the polymers are resistant to urea and 
reducing agents. Interestingly the polymeric species have a pI different from that 
of the monomeric protein which is represented by a number of spots with pIs 
ranging between 5-6. This is different from what we have seen in 293T cells, 
where the pI of the monomer is approximately 7. The dimer, of approximately 
25 kDa, has a pI >9.5, which is the limit of the strip. The larger species are 
characterized by pIs decreasing gradually towards neutrality up to a MW of 
approximately 250 kDa. These latter components migrate at a position 
corresponding to that of the monomers, with a slightly acidic pI. This 
experiment suggests a radical change of structure in the transition from 
monomer to dimer, involving the exposure of residues with a positive charge 
  49and the burying of negative residues. Furthermore, the results indicate the 
existence of two structurally defined populations of polymers of different MW. 
The oligomers ranging between 25 and 100/200 kDa and the >250 kDa 
polymers. The presence of oligomers characterized by alkaline pI strongly 






Figure 20. 2D-PAGE of E. coli CSTB immunoprecipitated with anti HA(F-7) abs. Staining 
with anti-HA(Y11) abs.  
 
4.2. A CSTB POLYMERIZING FACTOR 
The results described above suggest that the mechanism of CSTB 
polymerization is the same in prokaryotes and eukaryotes,  implying the 
existence of a conserved factor(s) responsible for the process. This may be 
useful, since, contrary to mammalian cells, E. coli does not express endogenous 
CSTB, offering a background free system to study CSTB polymerization. Thus, 
we have sought the putative polymerizing factor (PF) in the E.  coli protein 
extract with the following experiments.  
 
  504.2.1. THE POLYMERIZATION ASSAY 
The HA-CSTB monomer was purified by electroelution  from E. coli cells 
transformed with the pET16b-HA-CSTB expression vector. A polymerization 
assay was carried out by mixing HA-CSTB monomers with 10 μg of E. coli 
protein extract from cells transformed with the empty vector. The samples were 
analysed by SDS−PAGE and western blot (Figure 21, lane 3). A similar 
experiment was  carried out using the protein extract from human 293T cells 
(lane 2). Lane 1 contains the untreated monomer that shows a weak band in the 
position of the dimer and two very faint higher MW species. The addition of the 
protein extract from both E. coli and 293T cells drastically decreases the amount 
of monomeric CSTB and shows a strong polymeric pattern with components up 
to 90−100 kDa.  Once again, the two patterns obtained with prokaryotic and 





Figure 21. Polymerization assay. HA-CSTB monomer untreated (lane 1) and incubated with 
1 mg/ml of protein extract from 293T (lane 2) and E. coli cells (lane 3) lysed in buffer 1. 
Western blot analysis with anti HA(F-7) abs. No reducing agents added. 
 
In order to determine the amount of total E. coli protein extract necessary to 
polymerize CSTB, equal amounts of monomer were incubated with increasing 
concentrations of protein extract (Figure 22 lanes 3-7). The untreated monomer 
is in lane 1 and the protein extract alone is in lane 2. The intensity of the 
  51polymeric bands increases with the increase of the protein extract and 50 μg/ml 
of protein extract is sufficient to obtain an easily detectable polymerization. This 






Figure 22. Polymerization assay. HA-CSTB monomer untreated (lane 1) and incubated with 
increasing concentrations of protein extract from E. coli cells lysed in buffer 1. Western blot 
analysis with anti HA(F-7) abs. No reducing agents added. 
 
4.2.2. CHARACTERIZATION OF CSTB POLYMERIZING FACTOR 
BY COLUMN CHROMATOGRAPHY. 
The following  experiments show that PF can be further characterized by 
fractionating total E. coli protein extract by column chromatography. 2 mg total 
E. coli cell extract from cells transformed with the empty pET16b-
HA  expression vector, were fractionated on a Tricorn Superdex®200 
(Amersham) column (Figure 23). 30 samples containing 0.5 ml fractions were 
collected. Fractions 9-22 contain the excluded volume. Fractions  23-34 
represent the size fractionation volume ranging between approximately 10 and 
100 kDa. We have mixed the HA-CSTB monomers with 5ul (approximately 0.5 
μg protein) of each column fraction. As expected, the  fractions from the 
excluded peak induce polymerization without a defined pattern. This may be due 
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fractionation in this region. Fractions  23−34 show a weaker polymerizing 
activity in the initial and final samples of the column, while the middle fractions 
show a stronger activity, suggesting a peak shape in the region of 40−80 
kDa.  The polymerization assay was repeated with fractions 23−34 utilizing 
monomers obtained from 4 different CSTB mutants.  
 
   
 
 
Figure 23. Polymerization assay of wt HA−CSTB monomers added to the protein extract 
fractions of a superdex 200 column. No DTT added. Western blot analysis and staining as 
in figure 22. 
 
Figure 24 shows the fractionation assay on the same column as in figure 23 
using monomers from the G4R EPM1 natural mutant (A). Again, the 
polymerizing activity is present in fractions 24−30. B shows that DTT addition 
depolymerizes CSTB although some resistant high MW species remain. 
 





Figure 24. Polymerization assay of G4R HA−CSTB monomers added to the protein 
extract fractions of a superdex 200 column. Western blot analysis and staining as in figure 
22. A: minus DTT, B: plus 50 mM DTT.  
 
Figure 25 represents a similar experiment carried out with monomers obtained 
from the Δ68 EPM1 natural mutant. Polymerization occurs in the same fractions 
and with a very similar distribution (A) as in figure 23. B shows that the addition of 










Figure 25. Polymerization assay of Δ68 HA−CSTB monomers added to the protein extract 
fractions of a superdex 200 column. Western blot analysis and staining as in figure 22. A: 
minus DTT, B: plus 50 mM DTT.  
 






Figure 26. Polymerization assay of cysteine minus HA−CSTB monomers added to the 
protein extract fractions of a superdex 200 column. Western blot analysis and staining as in 
figure 22. No DTT added. A: C3/64A. B: C3/64S. 
 
The most interesting result is in figure 26, where monomers isolated from the 
cysteine minus mutant were  used for the assay. These monomers are not 
polymerized by any of the gradient fractions. This is true whether the cysteines 
are substituted by serine (A) or alanine (B). Polymerization occurs also 
with monomers that contain only one cysteine either in position 3 or 64 (not 
shown), suggesting that one cysteine  is necessary and sufficient to allow 
polymer formation. Fractions 24−31 of the Superdex 200 column were pooled 
and loaded onto a monoQ ion exchange column (Amersham) (Figure 27). The 
elution was on a 0−1M NaCl gradient, in 20mM TRIS pH7.9. 
The polymerization assay was carried out only with wt monomers, as described 
above. The beginning and the end of the gradient are in fractions 8 and 54. 
Polymerizing activity is evident in fractions 24−30. To check the MW of the 
polymerizing activity obtained from the mono Q column, we have 
loaded fractions 24, 26, 27, 28, 29 and 30 separately on a Tricorn Superdex® 75 
column. (Amersham).  





Figure 27. Polymerization assay of wt HA−CSTB monomers added to the protein extract 







Figure 28. Polymerization assay of wt HA−CSTB monomers added to the protein extract 
fractions of a superdex 75 column, as indicated. No DTT added. Western blot analysis and 
staining as in figure 22. 
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Figure 29. Polymerization assay of wt HA−CSTB monomers added to the protein extract 
fraction 26 of a superdex 75 column, as indicated. No DTT added. Western blot analysis and 
staining as in figure 22.  
 
The analyses of fraction 24-30 are shown in figure 28. Fraction 11 of the 
superdex 75 column contains the highest activity in all samples tested. Fraction 
26 was analysed in detail (Figure 29). The highest polymerizing activity 
observed in fractions 11/12 suggests that PF has a MW ranging between 50 and 
70 kDa.  .  
These data show that E. coli protein extract contains a protein of approximately 
70 kDa MW that triggers the polymerization of CSTB monomers by monomer 
addition. We think that this protein may be a redox related enzyme, possibly a 
modifier of the thiol group of cysteine. In fact, the cysteine minus mutant does 
not polymerize, while wt and mutant proteins, containing this 
aminoacid residue, polymerize. It is interesting to notice that the polymerizing 
activity that we describe refers to the generation of oligomers, while we do not 
see species larger than 100 kDa.  
 
  575. EXPRESSION OF CYSTATIN B AND ITS 
MUTANTS IN SKNBE CELLS  
 
5.1. CSTB GENERATES AGGREGATES IN VIVO 
Since 293T cells tend to form foci during growth and are detached from the 
plate surface by the fixation procedure, we have chosen SKNBE neuroblastoma 
cells for the microscopic analysis. The in vivo phenotype induced by expression 
of rat CSTB and its mutants in SKNBE cells was analysed by 
immunofluorescence confocal microscopy (Figure 30). The distribution of the 
wt protein is similar in transfected and non-transfected SKNBE cells. The 
localization of the protein is mainly nuclear [34], although in transfected cells 
the protein is clearly detectable also in the cytoplasm. Following 24 Hr 
transfection, the localization of the substitution mutants is similar to that of wt 
rat CSTB. In contrast, the carboxy- and amino-terminus deletion mutants show a 
different distribution: the staining with anti-HA abs is barely detectable in the 
nuclear compartment and is strong in the cytoplasm (Figure 31). Furthermore, 
the signal is concentrated in randomly distributed aggregates of variable size and 
number, similar to the cytoplasmic inclusion bodies described by Rajan et al. 
[205]. In some cases, the aggregates are numerous and small (Δ68), in other 
cases we see larger aggregates which may result from the confluence of small 
ones (Δ64 and ΔE1). In agreement with the nuclear presence of the endogenous 
protein, the same cells are stained by the anti-CSTB abs both in the nucleus and 
in the cytoplasm, and aggregated forms are also detected.  
 
Figure 30. Expression of CSTB. Confocal microscopy analysis of SKNBE cells transfected 
24 hr with CSTB wt and aminoacid substitution mutants as indicated. Staining with anti-
CSTB and anti-HA Abs. Co-localization is shown. Bar: 5 μm.   
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Figure 31. Expression of CSTB. Confocal microscopy analysis of SKNBE cells transfected 
24 hr with deletion mutants of CSTB as indicated. Confocal microscopy analysis as in 
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Figure 32. Time course of transfection of SKNBE cells with pEGFP fusion constructs of wt 
and mutants CSTB. The percentage of transfected cells shown in the histogram on the left is 
compared with the percentage of cells containing CSTB aggregates on the right. The latter 
value is calculated as the ratio of aggregate containing over transfected cells. Fluorescent 
aggregates generated by the CSTB fusion proteins are shown on the right of the histograms. 
The transfected constructs are indicated over each histogram. Bar: 5 μm. 
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the rate of aggregate formation throughout this period (Figure 32). The ΔCys 
mutant, that seemed to modify the polymerization properties of CSTB, and two 
natural EPM1 mutants were chosen for this experiment. The proportion of 
transfected cells is relatively constant up to 7 days when, in most samples, a 
slight decrease becomes visible. The exception is the Δ68 mutant that shows a 
decline of the transfected cell number. The green fluorescent protein (EGFP) 
alone, up to 7 days after transfection, does not produce detectable aggregates 
(panel A). The wt CSTB fusion construct starts generating aggregates 48 Hr 
after transfection and the number of positive cells increases gradually for 7 days, 
when approximately 50% of the transfected cells contain CSTB inclusions 
(panel B). The G4R mutant shows a steeply growing curve where, from day 5 to 
7, 70-90 % of the transfected cells contain aggregates (panel C). After 24 Hr 
transfection, the Δ68 fusion generates aggregates already in 20% of the cells 
(panel D) and, at day 5, almost 100% of the cells contain aggregates. The time 
coincides with the decrease of transfected cell number due to death .  
The  ΔCys fusion does not produce detectable aggregates until day 7, when 
approximately 30% of the transfected cells are affected (Figure 15E). This result 
is interesting as we have seen that the transfected ΔCys mutant does not show 
detectable oligomers, altering the polymerization pattern of CSTB (Fig. 15). The 
observation is also in good agreement with figure 29, where the ΔCys mutants 
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1. INTERACTION OF CYSTATIN B WITH 
CYTOPLASMIC PROTEINS 
Di Giaimo et al. [3] have shown that, in rat cerebellum, CSTB interacts with a 
number of cytosolic proteins involved in the cytoskeletal function. Two of them, 
NFL and β-spectrin, are exclusive of the nervous system and the authors have 
suggested that the binding of CSTB with CNS-specific proteins can be at the 
basis of the CNS-specific phenotype associated with EPM1.  
We have obtained comparable results analysing CSTB interactions in the 293T 
human cell line, confirming the binding of the protein with RACK1, NFL and β-
spectrin. We have extended the list of the CSTB-binding proteins through a 2D-
PAGE analysis and found another CNS-specific partner, neuronal copine. 
Neuronal copine belongs to the copine family of proteins which, upon Ca2+ 
activation, bind phospholipid membranes through the action of two C2 domains 
in the N-terminal region of the protein. Their C-terminal domain interacts with a 
number of intracellular target proteins [206-207]. Thus, copines are thought to 
mediate the Ca2+-dependent association of target proteins with phospholipides, 
regulating their intracellular localization and activity and being involved in 
growth control, cell cycle, apoptosis and cytoskeletal organization. Tomsing et 
al [207] have shown that copines bind preferentially coiled-coil domains of 
target proteins, among which there are β-actin and the CSTB partner brain β-
spectrin [206-207]. Nakayama et al [208] have suggested that neuronal copine 
may have a role as a Ca2+ sensor in postsynaptic events, in contrast to the 
known role of other “double C2 domain-containing proteins” such as 
synaptotagmin I, in presynaptic events. Interestingly, CSTB interacts also with 
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and Marialuisa Melli, unpublished]. It is possible to propose that CSTB, by 
interacting with all these partners, is also involved in pre- and post-synaptic events. 
The involvement of CSTB in vesicle traffic, cytoskeletal modelling and calcium 
metabolism is further implicated by its interaction with annexin A2 11 and A8 
that we have observed both in the yeast two hybrid system and by 2D-gel. 
Annexins are characterized by a conserved membrane-binding domain Ca2+-
regulated and a N-terminal domain of protein interaction, unique for a given 
member of the family. They can associate with negatively charged 
phospholipids in a Ca2+-dependent and reversible manner. This property links 
annexins to Ca2+ signalling and membrane-related events [209-210]. In 
particular, annexin A2 is implicated in the organization of membrane lipids at 
sites of actin cytoskeleton attachment [211-212].  Annexin A2 is also involved 
in Ca2+-regulated exocytosis and endocytosis [211-212]; this may correlate with 
the isolation by the two hybrid system of a number of proteins involved in 
vesicle traffic and cytoskeletal modelling (clathrin light chain, α−tubulin and the 
microtubule-binding proteins dynactin subunit p25 and kinesin which is 
involved in anterograde axonal transport of synaptic vesicles) [Rossella Di 
Giaimo and Marialuisa Melli, unpublished]. Annexin A2 is also implicated in 
the regulation of the Ca2+ channels in the sarcoplasmic reticulum [209-
210].  Interestingly we have found another protein associated with ER Ca2+-
regulated function, calreticulin, which is the major Ca2+ binding protein in ER 
lumen, where it is involved in protein glucosylation through the 
calnexin/calreticulin cycle [213-214]. While annexin A2 has a nuclear export 
signal in its N-terminal domain and may be involved in RNA nuclear export 
[209-210], annexin A11 has been detected as a nuclear protein that translocates 
from the nucleoplasm to the nuclear envelope in cells at prophase [215-216]. It 
is worth noting that CSTB is mainly localized in the nucleus, although its 
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of annexin A11 is at the midbody, where it probably functions in the terminal 
phase of cytokinesis, in the trafficking, or insertion  and fusion of the new 
membrane that is known to  be required for abscission [217].   Rossella Di 
Giaimo and Marialuisa Melli (unpublished) have isolated  another protein 
essential for cytokinesis, the actin binding protein prophilin. Although actin has 
never been individuated as a CSTB interactor, both sets of data 
(immunoprecipitation and two-hybrid experiments) define proteins that interact 
with actin, including thymosin beta−10, which regulates actin polymerization 
[Rossella Di Giaimo and Marialuisa Melli, unpublished].  
With the two different approaches used in our laboratory, the two-hybrid system 
and the immunoprecipitation analysis, we have identified both direct- and 
indirect-CSTB interactors. It is interesting that many of the CSTB partners 
interact with each other and are involved in the same cellular process, the 
cytoskeletal function. Altogether, our data seem to draw CSTB in the Ca2+-
mediated cytoskeletal activity, and in particular in vesicle traffic at the 
membrane level. This function is at the basis of neuronal signal transmission. 
Interestingly, our immunoprecipitation experiments with the EPM1 mutants of 
CSTB suggest that its cytoskeletal function could be altered in EPM1. In fact the 
absence of interaction between the Δ68 mutant and RACK1 indicates that this 
mutation changes the structure of the multiprotein complex.  
In conclusion, these experiments show that CSTB binds many different proteins, 
some of which very large. As CSTB entails 100 aminoacids only, it seems very 
reasonable that the interaction with the partners is mediated by CSTB polymers. 
 
2. CYSTATIN B IS POLYMERIC IN VIVO 
So far, CSTB has been described as a protein that, in vivo, is monomeric and , in 
vitro, is prone to amyloid fiber formation [105]. Cystatins have been associated 
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hereditary amyloid angiopathy and is a major constituent of the plaques found in 
the brain of the patients. Another common finding is the presence of cystatin A 
and B in the senile plaques of the Alzheimer and Parkinson diseases, and of 
senile dementia patients. Our results show that CSTB in vivo has a polymeric 
structure very resistant to denaturation and its over-expression generates cellular 
aggregates. Manning and Colòn [218] have described a number of proteins 
characterized by high kinetic stability and resistance to SDS denaturation, that 
require boiling for any change in structure. Interestingly, some of these proteins 
are polymeric and reach in β-sheets. We find that the polymeric structure of 
CSTB is resistant to 20 min boiling in 1% SDS and this is confirmed by the very 
similar distribution pattern of polymers from cells lyzed plus and minus 1% 
SDS.  According to Manning and Colòn [218]  the specific stabilizing 
characteristics of SDS resistant proteins are the presence in the structure of 
disulfide bonds, oligomeric interfaces and bound metals. These features are also 
present in CSTB polymers that seem to bind cupper as well [Rossella Di 
Giaimo, Elena Cipollini, Marialuisa Melli, unpublished]. The resistance of the 
polymers to 8 M urea confirms their exceptional stability. This recalls the 
resistance to SDS and 8M urea of oligomers from amyloid plaques of Alzheimer 
disease patients, described by Walsh et al. [219]. 
In order to find out whether the polymerization of CSTB is artifactual, due to the 
presence of the highly charged SDS molecule, we have analysed the MW of the 
native protein by SDS-free size fractionation on column chromatography [220-
221]. In a native extract, the fractionation of a protein that interacts with partners 
of different MW may not reflect precisely the size of the protein itself. The low 
MW components may fractionate in the high MW region of the column. In fact, 
the already mentioned predominance of monomers in the linear part of the 
column and the presence of polymers of variable size in the high MW fractions, 
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other proteins. The bias toward monomers, in the light region of the column, 
could also be due to higher sensitivity to boiling in 1% SDS of the intermediate 
MW, as compared to the larger components. Alternatively, some of the 
monomers/dimers are complexed with proteins that increase the size of CSTB. 
However, the result of this experiment shows clearly that polymeric CSTB from 
a native protein extract of 293T cells fractionates in the high MW region of the 
column, and is separate from monomers and dimers. This result confirms the 
existence in 293T cells of CSTB monomers and polymers as real components, 
which are independent of the method of cell lysis. The mass spectrometry 
analysis confirms the homopolymeric nature of the high MW species as well as 
the absence of gross modifications in the molecule.  
pH has been used by several authors to alter the conformation of SDS and urea 
resistant prion and amyloid proteins [222-223]. Accordingly, CSTB polymers 
are unfolded either by increasing the pH or by increasing the concentration of 
GSH, a reducing agent that acts like DTT or β-METOH. Consistent with this 
result, oxidation by addition of increasing concentration of H2O2 triggers the 
polymerization of CSTB. During this reaction the trimer seems to become 
particularly stable and, at the concentration of 1M H2O2, polymers and trimers 
are quite resistant to the reducing activity of β-METOH. We can conclude that 
the CSTB polymers are physiological and show features similar to those of β-
amyloid structures. These characteristics are typical of proteins regulated by the 
redox microenvironment [200]. 
 
3. CYSTATIN B MUTANTS ARE POLYMERIC 
Since polymeric CSTB may be related to its cytoskeletal function and the 
truncation mutant associated with EPM1 alters the multiprotein complex, we 
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relation to their polymerization properties. Our results show that none of the 
mutants, that we have constructed, inhibits the capacity of CSTB to generate 
polymers. However, this does not exclude the existence of differences between 
the structure and stability of the wt and mutant polymers. A different 
organization of the polymers is shown by the cysteine minus mutants. The 
presence of at least one cysteine is sufficient to generate the wt polymeric 
pattern and this is in agreement with the presence of only one cysteine at 
position 3 in the great majority of the species, including man. The strong 
decrease of the oligomers, observed in the absence of cysteines, is interesting 
and in agreement with our results on the effect of redox on CSTB structure. 
Clearly the cysteine is not required to obtain dimers and high MW polymers but 
is crucial to stabilize and perhaps regulate the intermediate MW species.  
Several authors have shown that amyloid fibers in vitro are generated by an 
initial event of domain swapping [123-224]. Staniforth et al. [2] have 
demonstrated that, in cystatins, this event occurs by a rearrangement of loop 1 
and that amyloid fibers grow by dimeric addition. This is not true for cellular 
CSTB, where polymers grow by monomer addition, and are insensitive to 
amminoacid substitutions in loop 1.  We can conclude that in the two cases 
polymerization occurs differently. The presence, in vivo, of chaperon-like and/or 
redox response proteins may be very important to this process [200,204]. 
 
4. MOLECULAR MECHANISM OF 
CYSTATIN B POLYMERIZATION 
Under physiological conditions native CSTB monomer does not self assemble 
and the denatured monomer shows a modest polymerization, in agreement with 
the denaturing conditions and prolonged times required for in vitro fibrillation of 
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incubated with a cell protein extract (eukaryotic or prokaryotic) or a cellular 
fraction containing proteins of about 50-70 kDa (and ionic strength 
corresponding to 150-550 mM NaCl). Furthermore, eukaryotes and prokaryotes 
generate undistinguishable CSTB polymers both in vivo and in the 
polymerization assay. Altogether these data point to the existence of a 
polymerizing factor(s), highly conserved in evolution, that can olygomerize 
CSTB when it contains a cysteine, but that is not sufficient to generate 
molecular species larger than 100 kDa. It is possible that these species require 
the presence of other factor(s) or an energy source that are lost during the lysis 
of the cells. It is interesting to notice that CSTB interacts with the heat shock 
proteins 70, 73, 86, 90, and ERP99 [Rossella Di Giaimo and Marialuisa Melli, 
unpublished], which could play a role in its polymerization. Chaperone 
activities, in fact, are conserved in evolution, may function alone or with other 
chaperones and usually require ATP or GTP [225]. The lack of oligomerization 
in vivo and in vitro of the cysteine minus mutants, suggests that a cysteine is 
necessary for the recognition of CSTB by the oligomerizing factor. A single 
cysteine can function as a sensor being the target of various modifications i.e. 
nitrosilation, sulfonation, sulfenilation, glutathionylation, cysteinyl−glycylation 
and homocysteinylation. These modifications can generate binding surfaces that 
allow structural changes [200]. Structural changes certainly occur during the 
transition from monomer to oligomers. This is shown by the migration 
properties of the oligomers in the 2D gel of figure 20. The gradual change of the 
isoelectric point could be consistent with a different modification of the SH 
residue of cysteine, resulting in structural change. The instability of the 
oligomers contrasts with the high stability of the largest polymers, characterized 
by a slightly acidic pI and acidic pH favours polymerization. The instability of 
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responsible for amyloid fiber formation. 
 
5. EXPRESSION OF CYSTATIN B AND ITS 
MUTANTS IN SKNBE CELLS 
Amyloid-like proteins in yeast are described as physiological proteins through 
which individuals can be preadapted to selective niches . In mammals they are 
usually associated with pathologies. Amyloid formation involves the generation 
of soluble oligomers as a result of relatively non specific interactions and/or 
specific structural transitions such as domain swapping. These precursors 
acquire a distinct morphology and become protofibrils that later assemble into 
mature fibrils. It is generally accepted that amyloid formation is triggered by a 
nucleation event that occurs stochastically and may occur more frequently at 
high concentration of the protein [226-229]. Given the characteristics of 
polymeric CSTB, we have analysed the effect of its over-expression in 
neuroblastoma cells. The appearance of cellular aggregates is almost immediate 
in cells transfected with the deletion mutants, and takes longer time with the wt 
and the G4R substitution  mutant. All mutants tested generate aggregates except 
the cysteine minus constructs. In the latter case, it is not clear whether aggregate 
formation is slowed down or actually not present. Only a small proportion of 
cells are affected after 7 days of transfection, when the cells are over-confluent 
and start to die. Interestingly, the ΔCys mutant does not show a detectable 
amount of intermediate MW oligomers and a growing body of evidence 
suggests that oligomers are the toxic species that give rise to amyloid diseases 
[219,229-230]. 
 
  706. CONCLUSIONS 
 
This work makes the following points.  
 
1. The nature of the possible partners of CSTB suggests a cytoskeletal function 
involved in neural transmission. 
2. The existence of a physiological polymeric protein with amyloid-like 
properties in mammalian cells. Berson et al. [231] have shown that the Pmel 17 
melanocyte protein polymerizes into amyloid-like fibrils during the process of 
melanosome biogenesis. Prions with positive functions for the cell have been 
widely studied in yeast. E. coli and Salmonella form amyloid-like extracellular 
fibrils orchestrated by two different operons [232]. In synthesis we may say that 
fibril formation is an evolutionary conserved mechanism for creating 
biologically active quaternary structures. The unique properties of amyloid 
structures have been exploited by several species for specific purposes [233]. 
We think that also polymeric CSTB belongs to this category of proteins, being 
functional because of its amyloid-like properties.  
3. The results envisage a molecular mechanism that could explain neural 
degeneration at least in the EPM1 patients heterozygous for both promoter and 
point mutations. In fact we find that the natural mutants are stable proteins that 
within 24 Hr already generate amyloid aggregates in neuroblastoma cells. This 
strongly suggests that, when these alleles are present, the same happens in the 
CNS of patients. A similar suggestion as been made by Ceru et al. [234] on the 
basis of the aggregation propensity of the G4R EPM1 mutant. In this context, it 
is interesting to notice that many prion diseases lack cerebral plaques that stain 
with amyloid specific dyes [229]. This could be also true for EPM1, where 
cerebral aggregates were not described.  
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1. PLASMIDS 
1.1. EUKARYOTIC EXPRESSION VECTORS 
1.1.1.pRK7-HA 
Wt and mutant CSTB sequences were inserted in the pRK7 vector containing 
one copy of the HA tag sequence (pRK7-HA) upstream from the Bam HI site (nt 
921-959). The fusion protein expression is under the control of the CMV 
promoter (nt 60-598). SV40 polyadenylation signal (nt 1028-1158) downstream 
of the multiple cloning site (MCS) directs proper processing of the 3' end of the 
fusion protein mRNA. The ampicillin resistance gene (nt 2733-3593) allows 
propagation and selection in E. coli. The plasmid backbone also provides a pUC 
origin of replication (nt 3738- 4411) for propagation in E. coli and a f1 origin (nt 
1941- 2269) for single stranded DNA production. 
 
HA
  73Poly-linker sequence of pRK7-HA vector: 
 
                  HindIII                   BmgBI 
aaa   HA tag sequence   901 ACCTCGGTTC TAAGCTTACC ATGGCCTACC CCTACGACGT GCCCGACTAC 
 
                                                      XmaI 
                                                      SmaI 
               BamHI                                  AvaI 
  951 GCCTCCCTCG GATCCGCTCT TTATCTTCTT CTGTGGGGGC GATCCCCGGG 
 
      EcoRI  ClaI   SfiI                              PsiI 
 1001 GAATTCAATC GATGGCCGCC ATGGCCCAAC TTGTTTATTG CAGCTTATAA 
 
 1051 TGGTTACAAA TAAAGCAATA GCATCACAAA TTTCACAAAT AAAGCATTTT 
 
             BsmI 
 1101 TTTCACTGCA TTCTAGTTGT GGTTTGTCCA AACTCATCAA TGTATCTTAT 
 
               ClaI 
 1151 CATGTCTGGA TCGATCGGGA ATTAATTCGG CGCAGCACCA TGGCCTGAAA 
 
1.1.2. pEGFP-C1 
For the cell count experiments, wt and mutant CSTB sequences were inserted in 
the pEGFP-C1 vector (BD Biosciences Clontech). 
The MCS in pEGFPC1 is between the EGFP coding sequences and the SV40 
poly A. Genes cloned into the MCS are expressed as fusions to the C-terminus 
of EGFP. SV40 polyadenylation signals downstream of the EGFP gene direct 
proper processing of the 3' end of the EGFP mRNA. The vector backbone also 
contains a SV40 origin for replication in mammalian cells expressing the SV40 
T-antigen. A neomycin resistance cassette (Neor), consisting of the SV40 early 
promoter, the neomycin/kanamycin resistance gene of Tn5, and polyadenylation 
signals from the Herpes simplex virus thymidine kinase (HSV TK) gene, allows 
stably transfected eukaryotic cells to be selected using G418. A bacterial 
promoter upstream of this cassette expresses kanamycin resistance in E. coli. 
The pEGFP-C1 backbone also provides a pUC origin of replication for 
propagation in E. coli and a f1 origin for single stranded DNA production. 
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(*) The Xba I and Bcl I sites are methylated. 
 
1.2. PROKARYOTIC EXPRESSION VECTOR 
1.2.1. pET16b 
Wt and mutant CSTB sequences were inserted in the pET16b-HA vector, 
generated from the pET16b vector (Novagen) as described in paragraph 2.4.  
The pET-16b vector (Cat. No. 69662-3) carries an N-terminal His•Tag® 
sequence followed by a Factor Xa site upstream of three cloning sites. The target 
gene is cloned under the control of the T7lac promoter, which allows to induce 
  75the expression of the target gene by addition of IPTG to the bacterial culture. 











1.2.2. pET11a-HUMAN C3S CSTB 
pET11a-human C3S CSTB vector was a kind present from Eva Zerovnik. 
 
  762. PREPARATION OF PLASMIDIC CONSTRUCTS 
2.1. pRK7-HA-CSTB WT 
PCR AMPLIFICATION 
Wt rat CSTB sequence was cloned in the pRK7-HA between the Bam HI and 
Eco RI sites.  
The restriction sites Bam HI and Eco RI were inserted at the 5’ and 3’-terminus 
of CSTB cDNA, respectively, by PCR amplification using the 5’BamH1 cstb 
terminal primer and the 3’ EcoRI cstb terminal primer (see Table 2). 
The PCR reaction was:  
 
50 ng template DNA  
1X DNAZyme buffer with 1.5 mM Mg2+ (Finzyme) 
0.2 mM dNTPs 
0.2 μM 5’primer  
0,2 μM 3’primer  
3 U DNAZyme Taq (Finzyme) 
H2O to a final volume of 200 μl 
 
The thermal cycler was programmed as follows: 
 
1 time: 95°C  for 5 min 
30 times: 95°C  for 5 min 
  65°C  for 40 sec 
  72°C  for 1 min 
1 time: 72°C  for 10 min 
 
DNA AGAROSE GEL  
At the end of the reaction, the PCR product was checked on a DNA 2% agarose gel. 
 
The gel was run in TAE 1X buffer supplemented with 5 μg/ml Etidium bromide.  
 
  77•  for 2% agarose gel, add 2g agarose powder to 100 ml TAE 1X + 5 μg/ml 
EtBr buffer,  
•  heat the mixture up to boiling  
•  pour the mixture on the apposite horizontal plate (BioRAD 6,5x10 cm) and 
let it cool for at least 30 min  
•  transfer the gel in the horizontal electrophoresis cell containing the TAE 1X 
+ 5 μg/ml EtBr buffer  
•  add the DNA loading buffer (1x final concentration) to the samples and load 
on the gel 
•  run the gel at 70/80 V for at least 1 h. 
 
ORGANIC SOLVENT EXTRACTION AND ETHANOL PRECIPITATION OF DNA 
The PCR product was purified by organic solvent extraction, adding 1 volume 
of phenol saturated with Tris pH 8-chloroform 50:50. Residual phenol was 
removed by two extractions with equal volumes of chloroform. The water phase 
was recovered and precipitated in 0.3 M NH4-acetate pH 5,3 and 3 volumes of 
100% ethanol, incubated at least 45 min at –20°C and centrifuged 20 min at 
17000 g. The pellet was washed in 70% ethanol and dried in a vacuum fuge. A 
small aliquot of water phase was used for the quantification of DNA on an 
agarose gel.  
 
RESTRICTION DIGESTION 
The amplified cDNA and the pRK7-HA vector were digested with the Bam HI 
and Eco RI enzymes as follows:  
 
2 μg DNA 
1X Multicore buffer (Promega) 
0.1 μg/μl BSA  
10 U BamHI (Promega) 
  7810 U EcoRI (Promega) 
 
Incubation at 37°C for 4 hr. 
 
The digested vector and the cDNA were purified by gel filtration using a 
Chromaspin 1000 and a Chromaspin 100 (Clontech), respectively. 
 
LIGATION 
The plasmid and the insert were ligated in a 1:3 ratio according to the following 
protocol: 
 
pRK7-HA-CSTB cDNA  
1X T4 ligase buffer with 1mM ATP (New England Biolabs) 
400 U T4 ligase (New England Biolabs)  
in a final volume of 10 μl  
 
Incubation at room temperature (RT) for 4 hr. 
 
The ligation product (pRK7-HA-CSTB) was precipitated in 0.3 M NH4-acetate 
pH 5,3 and 3 volumes of 100% ethanol as described above. 
 
E.COLI ELECTROPORATION 
pRK7-HA-CSTB was used to transform E. coli electrocompetent cells by 
electroporationwith the . E. coli cells used had a transformation efficiency of 
10
8-10
10 transformants/DNA μg. The electroporation was performed with the 
Gene-Pulser (Bio-RAD) electroporator and 0,2 cm cuvettes (Bio-RAD), pre-
cooled at –20°C. Electric pulse was –2.5 KV.  
 
•  unfrost, on ice, the electrocompetent cells  
•  mix a 30 μl aliquot of cells with 100 ng ligation product pellet  
•  transfer the mixture in a cuvette 
  79•  immediately after transformation, transfer cells in 960 μl of SOC medium in 
a 15 ml polyropilene tube and incubate 1 hr at 37°C, 250 rpm  
•  plate aliquots of cells (10, 50, 100, 200 and 600 μl) on selective medium (LB 
+ 0.02 g/ml Agar + 100μg/ml Ampicillin)  
•  incubate overnight (ON) at 37°C.  
 
PCR-COLONY SCREENING 
The recombinants were analysed by PCR-colony screening, according to the 
following protocol: 
 
Each E. coli colony was diluted in 30 μl H2O and lysed by boiling at 100°C, 10 
min. A few cells from each colony were plated on selective medium (LB + 0.02 
g/ml Agar + 100μg/ml Ampicillin). 
 
2 μl colony dilution  
1X DNAZyme buffer with 1.5 mM Mg2+ (Finzyme) 
0.2 mM dNTPs 
0.5 μM 5’BamH1 cstb terminal primer  
0.5 μM 3’EcoRI cstb terminal primer 
0.2U Taq DNAZyme (Finzyme) 
H2O to a final volume of 20 μl 
 
The termocycler was programmed as described above. 
The recombinant frequency was checked on a DNA 2% agarose gel. 
The construct was checked by sequencing with the Big Dye®Terminator v1.1 
Cycle Sequencing kit (Applied Biosystem), according to manufacturer’s 
instructions. 
The positive recombinants were grown in 1 ml of LB+100μg/ml Ampicillin, ON 
at 37°C, 250 rpm. Cells were pelletted at 4000 rpm 10 min, suspended in 
LB+15% Glycerol medium and stored at –80°C. 
  802.2. pRK7-HA-MUTANT CSTB: SITE DIRECTED MUTAGENESIS 
CSTB mutants were inserted in pRK7-HA between the Bam HI and Eco RI sites.  
All constructs were checked by sequencing. 
 
2.2.1. 5’ AND 3’ TERMINAL MUTANTS  
For the C3S and ΔE1mutants, the restriction site Bam HI and the 5’ terminal 
mutations were inserted by PCR amplification using specific 5’primers and the 
Eco RI site using the 3’EcoRI cstb terminal primer (see Table 2). 
For the Δ64, Δ68, Δtc and T87K mutants, the restriction site Eco RI and the 3’ 
terminal mutations were inserted by PCR amplification using specific 3’primers 
and the Bam HI site using the 5’BamH1 cstb terminal primer (see Table 2). 
 
The PCR reaction was as described in section 2.1 and PCR cycles were:  
 
1 time: 95°C  for 5 min 
10 times: 95°C  for 5 min 
72°C  for 1 min 40 sec 
20 times: 95°C  for 5 min 
69°C  for 40 sec 
72°C  for 1 min 
 
1 time: 72°C  for 10 min 
 
The cloning of CSTB mutants in pRK7-HA was as described for the cloning of 
the wt protein in the same vector. 
 
2.2.2. pRK7-HA-CSTB G4R 
pRK7-HA-CSTB vector was digested with Bss HII restriction enzyme as 
follows: 
 
  818 μg pRK7-HA-CSTB wt 
1X H buffer (Promega) 
0.1 μg/μl BSA  
50 U BssHII (Promega) 
 
Incubation at 37°C for 4 hr. 
 
The digested vector was precipitated in 0.3 M NH4-acetate pH 5,3 and 3 
volumes of 100% ethanol, as described above and digested with BamH1 
restriction enzyme as follows: 
 
8 μg pRK7-HA-CSTB wt 
1X buffer E (Promega) 
0.1 μg/μl BSA  
50 U BamHI (Promega) 
 
Incubation at 37°C for 4 hr. 
 
The digested vector was purified by gel filtration using a Chromaspin 1000 
(Clontech). 
 
The two complementary sequences 5’BamH1 cstb G4R BssHII and 3’BamH1 
cstb G4R BssHII were annealed in 0.2 M Na-acetate by denaturation at 70-
100°C for 3 min and renaturation by slow cooling. The double strand oligo was 
then inserted directly into the BamHI-BssHII sites of the pRK7-HA-CSTB 
vector. The vector: insert ratio in the ligation reaction was 1:400. 
 
2.2.3. INTERNAL SINGLE SUBSTITUTION MUTANTS 
The Q71P, V59Q, C64S, V48D, V48A and G50A mutations were inserted by 
three PCR amplifications:  
  82PCR1: amplification to insert the Bam HI site and the internal mutation using 
the 5’ BamH1 cstb terminal primer and the 3’ primer with the specific mutation; 
PCR2: amplification to insert the internal mutation and the Eco RI site using the 
5’ primer with the specific mutation and the 3’EcoRI cstb terminal primer; 
PCR3: amplification to generate the whole cstb mutant sequence using the 5’ 
BamH1 cstb terminal primer and the 3’EcoRI cstb terminal primer to amplify a 
mix of the products of PCR1 and 2 which is used as template cDNA. 
The PCR cycles were as described in section 2.2.1. 
The cloning was according to the protocol described for the cloning of the wt 
protein in the same vector. 
 
2.2.4. DOUBLE SUBSTITUTION MUTANTS 
CSTB C3/64S double substitution mutant was generated by PCR amplification 
of the single mutant C64S with the 5’ BamH1 cstb C3S and 3’EcoRI cstb 
terminal primers as described in section 2.2.1. 
CSTB VG48/50A double substitution mutant was generated by PCR 
amplification from the single mutant V48A according to the protocol described 
in section 2.2.3. 
 
2.3. pEGFP-C1-CSTB CONSTRUCTS 
Wt and mutant sequences were inserted between the Xho I and Eco RI sites of 
the pEGFP-C1 vector (BD Biosciences Clontech). 
Xho I and Eco RI sites were inserted by PCR amplification using pRK7-HA 
CSTB wt or mutated as DNA template and specific terminal primers (in bold 
letters in Table 1). PCR reaction and cloning protocols were as described in 
section 2.2.1. 
 
  832.4. pET16b-HA 
The pET16b-HA vector was generated from the pET16b vector (Novagen).  
 
pET16b vector was separately digested with NcoI (Promega) and Bam HI 
restriction enzymes, as described in section 2.2.2. The His tag, Factor Xa and 
polylinker sequences were removed running the digested plasmid on a DNA 1% 
agarose gel, excising the vector fragment from the gel and recovering it using 
the QIAquick®Gel Extraction Kit (Qiagen).  
 
The two complementary sequences 5’Nco1-HA-polylinker and 3’ Nco1-HA-
polylinker were annealed in 0.2 M Na-acetate by denaturation at 70-100°C for 3 
min and renaturation by slow cooling. The double strand oligo was then inserted 
directly into the NcoI-BamHI sites of the pET16b vector. The vector: insert ratio 
in the ligation reaction was 1:400. 
 
The pET16b-HA vector obtained contains the HA tag sequence between NcoI 
and Bam HI sites and a new MCS. The frame between the HA tag and Bam HI 
site sequences is the same as in pRK7-HA, allowing the use of the same 5’ 
BamH1 cstb(wt or mutated) terminal primers (see table 1). 
 
          Nco1        HA tag                      BamH1 KpnI SmaI XhoI 
5’   TACCATGGCCTACCCCTACGACGTGCCCGACTACGCCTCCCTCGGATCCGGTACCCGGGCTCGAGCC   3’ 
 
 
2.5. pET16b-HA-CSTB CONSTRUCTS 
Wt and mutant sequences were inserted between the Bam HI and Xho I sites of 
the pET16b-HA vector. 
Xho I and Bam HI sites were inserted by PCR amplification using pRK7-HA 
CSTB wt or mutated as DNA template and specific terminal primers (in italic 
  84letters in Table 2). PCR reaction and cloning protocols were as described in 
section 2.2.1. 
 
The C3A mutant was generated and cloned as described in section 2.2.1., the 
C64A as described in section 2.2.3.and the C3/64A double substitution mutant 




5’ BamH1 cstb terminal primer   TATGGATCCATGATGTGTGGCGCGC 
3’ EcoRI cstb terminal primer  CCGGAATTCTCAGAAGTAGGTTAGCTC 
5’ cstbQ71P  GGGTGTTTCCACCCCTCCCTC 
3’ cstbQ71P  GAGGGAGGGGTGGAAACACCC 
3’ EcoRI cstb Δ68 ATAGAATTCTCACAAGTGCACACATTTTTC 
3’ EcoRI cstb Δtc TAGGAATTCTCATGAGGGAGGTTCAAACA 
3’ EcoRI cstb Δ64 TCAAGAATTCTCATTTTTCTTCGCCGACATCAAC 
5’ BamH1 cstb ΔE1 TATGGATCCTAGTGAAGTCTCAACTTGAAG 
5’ cstb V59Q  CCAACTTCTTCATCAAGGTTGATCAGGGCGAAGAAAAATGTGTGC 
3’ cstb V59Q  GCACACATTTTTCTTCGCCCTGATCAACCTTGATGAAGAAGTTGGG 
3’ EcoRI cstb T87K  CCGGAATTCTCAGAAGTAGGTTAGCTCATCGTGCTTTTCTTTGTCCTTCTGGTAAGAGG 
5’ BamH1 cstb C3S  CTATGGATCCATGATGTCTGGCGCGCC 
5’ cstb C64S   CGGCGAAGAAAAATCTGTGCACTTGAGGGTGTTTGAACCCC 
3’ cstb C64S   GGGGTTCAAACACCCTCAAGTGCACAGATTTTTCTTCGCCG 
5’ cstbV48D  CCTTCAGGAGACAGGTAGACGCCGGCACCAACTTCTTCATCAAGG 
3’ cstbV48D  CCTTGATGAAGAAGTTCCTGCCGGCGTCTACCTGTCTCCTGAAGG 
5’ cstbV48A  CCTTCAGGAGACAGGTAGCGGCCGGCACCAACTTCTTC 
3’ cstbV48A  GAAGAAGTTGGTGCCGGCCGCTACCTGTCTCCTGAAGG 
5’ cstbG50A  GGAGACAGGTAGTGGCCGCCACCAACTTCTTCATCAAGG 
3’ cstbG50A  CCTTGATGAAGAAGTTGGTGGCGGCCACTACCTGTCTCC 
5’ BamH1 cstb G4R BssHII  GATCCATGATGTGTCG 
3’ BamH1 cstb G4R BssHII  CGCGCGACACATCATG 
5’ cstbVG48/50A  GGAGACAGGTAGCGGCCGCCACCAACTTCTTCATCAAGG 
3’ cstbVG48/50A  CCTTGATGAAGAAGTTGGTGGCGGCCGCTACCTGTCTCC 
5’ XhoI cstb terminal primer   TATCTCGAGGAATGATGTGTGGCGCGC 
5’ XhoI cstb G4R  TATCTCGAGGAATGATGTGTCGCGCGCCATCCG 
5’ XhoI cstbC3S TATCTCGAGGAATGATGTCTGGCGCGCC 
5’Nco1-HA-polylinker CATGGCCTACCCCTACGACGTGCCCGACTACGCCTCCCTCGGATCCGGTACCCGGGCTC
GAGCC 
3’ Nco1-HA-polylinker  GATCGGCTCGAGCCCGGGTACCGGATCCGAGGGAGGCGTAGTCGGGCACGTCGTAGGG
GTAGGC 
3’XhoI CSTB terminal primer  CGATTCTCGAGTCAGAAGTAGGTTAGCTCATCG 
5’ BamH1 CSTB C3A  CTATGGATCCATGATGGCTGGCGCGCC 
5’ BamH1 CSTB G4R  TATGGATCCATGATGTGTCGCGCGCCATCCG 
5’ CSTB C64A   CGGCGAAGAAAAAGCTGTGCACTTGAGGGTGTTTGAACCCC 
3’ CSTB C64A   GGGGTTCAAACACCCTCAAGTGCACAGCTTTTTCTTCGCCG 
3’ XhoI CSTB Δ68 CGATTCTCGAGTCACAAGTGCACACATTTTTC 
3’ XhoI CSTB ΔTC CGATTCTCGAGTCATGAGGGAGGTTCAAACA 




  852.6. PLASMID DNA PURIFICATION 
Plasmid DNA was purified using the QIAGEN Plasmid Maxi Kit and QIAprep 
Miniprep Kit (Qiagen), according to manifacturer’s instructions. 
Bacteria cell coltures for maxipreps were in Terrific Broth medium, for 
minipreps were in LB. 
 
3. EXPRESSION OF CYSTATIN B IN 
EUKARYOTIC COLTURE CELLS 
3.1. CELL COLTURE 
Cells were grown in DMEM medium supplemented with 10% Fetal Bovine 
Serum (FBS), glutamine, penicillin/streptomycin and Na-pyruvate at 37°C in 
5% CO2. Cells were diluted 1:3 every 2 days. 
 
3.2. CELL TRANSFECTION 
3.2.1. TRANSFECTION OF SKNBE CELLS USING LIPOFECTAMINE PLUS 
SKNBE cells were transfected with Lipofectamine Plus (GIBCO), according to 
manufacturer’s instructions. 
 
3.2.2. TRANSFECTION OF 293T CELLS USING PEI 
31000 293T cells/cm
2were plated 16 hours before transfection. Cells were 
transfected with 5 μg/ml plasmid (pDNA) and 165 μM PolyEthylenImine (PEI) 
(Sigma-Aldrich) as follows. 
 
Transfection Solution Volumes (TS vol) were 4 ml for 10 cm petri dishes and 11 
ml for 175 cm2 flasks. 
 
  86•  Add 150 mM NaCl (sterile) to pDNA to a final volume of 1/20 TS vol, 
vortex 1 min and let the mixture to equilibrate at RT for 15 min 
•  Add 150 mM NaCl (sterile) to PEI to a final volume of 1/20 TS vol, vortex 1 
min and let the mixture to equilibrate at RT for 15 min. Use 0.33 μl 100 mM 
PEI/μg pDNA) 
•  Remove colture medium from the cells and add DMEM, incubate at 37°C in 
5% CO2 until transfection 
•  Add equilibrated PEI to equilibrated pDNA, vortex 1 min and let the mixture 
to equilibrate at RT for 30-35 min 
•  Prepare the Transfection solution adding 9/10 TS vol of DMEM to the pDNA 
+ PEI mixture 
•  Transfect cells removing the DMEM and adding the Transfection solution, 
incubate at 37°C in 5% CO2 for 3 hr 
•  Remove the Transfection solution from the cells and add fresh colture 
medium. Grow the cells at 37°C in 5% CO2 for 16 hr before harvesting. 
 
3.3. CELL LYSIS 
Cells were harvested by scraping in the colture medium, pelletted centrifuging 5 
min at 1000 rpm, RT. The pellet was thoroughly washed in 1X PBS and 
pelletted as described above. Lysis was carried out under three different 
conditions. 
 
3.3.1. CELL LYSIS IN BUFFER 1 (NON DENATURING CONDITIONS 
AND SONICATION) 
Cells were lyzed in 1X PBS containing 20% Glycerol, 0.4 mM EDTA, 1 mM 
DTT, 0.5% NP40, anti-protease and anti-phosphatase cocktail (Sigma).  
 
  87The samples were sonicated, on ice, 5 times for 5sec at 15% amplitude using the 
Sonifier®Cell Disruptor (Branson) with a 3mm microtip. The samples were then 
centrifuged at 13200 rpm, 4°C, and 30 min. The supernatants were collected, 
aliquoted and stored at –80°C. Protein concentration was determined using the 
Bio-Rad Protein Assay, according to manufacturer’s instructions. 
 
3.3.2. CELL LYSIS IN BUFFER 2 (DENATURING CONDITIONS AND 
SONICATION) 
Cells were lyzed in 1X PBS containing 1% SDS. The samples were boiled 10 
min and diluted 10 times in PBS, containing anti-protease and anti-phosphatase 
cocktail (Sigma), to a final concentration of 0.1% SDS. Diluted samples were 
sonicated as described in section 3.3.1. 
 
3.3.3. CELL LYSIS IN PROTEIN LOADING BUFFER (DENATURING 
CONDITIONS) 
Cells were lyzed in 1X Protein Sample Buffer and the samples were boiled 10 
min. 
 
4. EXPRESSION OF CYSTATIN B IN 
PROKARYOTIC CELLS  
Wt and mutant HA-CSTB was expressed in E.coli BL21 as follows. 
 
•  The day before induction, inoculate a single colony of E.coli BL21, 
transformed with the prokaryotic expression vector of interest, in 20 ml 
2XYT medium + 100μg/ml Ampicillin and incubate at 37°C, 240 rpm, ON.  
  88•  The following day dilute the bacteria 1:100 in 40 ml 2XYT medium + 
100μg/ml Ampicillin, incubate at 37°C, 240 rpm, for about 2 hr 
•  When the colture’s OD550 is 0.5, add 0.4 mM IPTG (isopropyl-beta-D-
thiogalactopyranoside) and incubate at 37°C, 240 rpm, 3 hr 
•  Harvest the cells centrifuging at 6000 g, 10 min, remove the colture medium  
•  Wash the bacteria pellet with 1XPBS and lyze cells with buffer 1 or 2 as 
described in sections 3.3.1. and 3.3.2. 
 
5. IMMUNOPRECIPITATION (IP) EXPERIMENTS. 
5.1. IP OF DENATURED PROTEIN EXTRACTS 
5.1.1. IP FOR WESTERN BLOT ANALYSYS 
Protein extracts from 293T cells, non transfected or transfected with pRK7-HA-
CSTB wt and mutated, lyzed in buffer 2 (see section 3.3.2.) were 
immunoprecipitated with mouse anti-HA (F-7) abs according to the following 
protocol. 
 
Preclearing of the protein extract: 
~ 800 μg protein extract 
20 μl 50% Protein A-Sepharose
TMCL-48 (Amersham Biosciences) 1XPBS  
1X anti-protease cocktail (Sigma), 
1X anti-phosphatase cocktail (Sigma) 
 
Gently mix for 3 Hr at 4°C. 
Centrifuge at 1000 rpm, 4°C and 5 min.  
 
Immunoprecipitation: 
Transfer the supernatant in a clean eppendorf and add 2 μg abs. Gently mix at 
4°C, ON. 
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IP-resin interaction: 
Add to the IP mixture 20 μl 50% Protein A-Sepharose
TMCL-48 (Amersham 
Biosciences) 1XPBS. 
Gently mix for 2 Hr at 4°C. 
 
Purification of the immunoprecipitated proteins: 
Load the IP on a Bio-Spin disposable chromatography column (BioRAD) and 
thoroughly wash it with cold 1XPBS.  
The immunoprecipitates are eluted in 0.1 M glycine. The acidic pH of the 
glycine is immediately neutralized with 3M TRIS pH 9. 
 
¼ of each IP was loaded on SDS-PAGE and analysed by western blot as 
described in section 6. 
 
5.1.2. IP FOR MASS SPECTROMETRY ANALYSIS 
30 mg protein extract from 293T cells transfected with pRK7-HA-CSTB wt, 
lyzed in buffer 2 (see section 3.3.2.) was immunoprecipitated with 40 μg mouse 
anti-HA (F-7) abs and 350 μl 50% Protein A-Sepharose
TMCL-48 (Amersham 
Biosciences) 1XPBS as described in section 5.1.  
 
5.2. IP OF NATIVE PROTEIN EXTRACTS  
5.2.1. IP OF 293T CELL PROTEIN EXTRACT FOR SDS-PAGE 
1.2 mg protein extracts from 293T cells, non transfected or transfected with 
pRK7-HA-CSTB wt and mutated, lyzed in buffer 1 (see section 3.3.1.) were 
immunoprecipitated with 20 μl 50% Protein A-Sepharose
TMCL-48 (Amersham 
Biosciences) 1XPBS and 3.2 μg mouse anti-RACK1 (BD Biosciences), 12 μg 
  90goat anti-NFL (Santa Cruz) and 6 μg goat anti-brain spectrin βI (C-19) (Santa 
Cruz) plus 6 μg goat anti-brain spectrin βI (N-19) (Santa Cruz) abs as described 
in section 5.1. For the IP with anti-RACK1 abs, Anti-mouse IgM (μ-chain 
specific) Agarose (Sigma) was used. Elution was in 30 μl of 2X2D-gel buffer. 
 
5.2.2. IP OF 293T CELL PROTEIN EXTRACT FOR 2D-PAGE 
15 mg protein extract from 293T cells transfected with pRK7-HA-CSTB wt, 
lyzed in buffer 1 (see section 3.3.1.) was immunoprecipitated with 17 μg mouse 
anti-HA (F-7) abs and 100 μl 50% Protein A-Sepharose
TMCL-48 (Amersham 
Biosciences) 1XPBS as described in section 5.1. Elution was in 100 μl of 2X2D-
gel buffer. 
 
5.2.3. IP OF E. COLI PROTEIN EXTRACT FOR 2D-PAGE 
1.6 mg protein extract from E. coli transformed with pET16b-HA-CSTB wt, 
lyzed in buffer 1 (see section 3.3.1.) was immunoprecipitated with 3.2 μg mouse 
anti-HA (F-7) abs and 24 μl 50% Protein A-Sepharose
TMCL-48 (Amersham 
Biosciences) 1XPBS as described in section 5.1. Elution was in 30 μl of 2X2D-
gel buffer. 
 
6. PROTEIN EXTRACT ANALYSIS 
6.1. SDS-POLYACRYLAMIDE GEL ELECTROPHORESIS (SDS-
PAGE) 
Most of the SDS-PAGEs were carried out in 12% polyacrylamide gels. Gels for 
β-spectrin and NFL were 6% polyacrylamide. All samples were boiled 20 min 
in Protein Loading Buffer before loading on the gel.  
  91Electrophoresis was carried out in vertical electrophoretic cells Mini-PROTEAN II 
(BioRAD), or Mini-PROTEAN III (BioRAD), applying 24 mA/gel.  
 
6.2. 2D-SDS-PAGE 
6.2.1. FIRST DIMENSION: ISOELECTRIC FOCUSING (IEF) 
IPG STRIP pH 3-10, 7 CM  
Sample preparation: 
15 μl IP from E. coli protein extract (see section 5.2.3) 
4 μl Bromophenol Blue 0.1 % 
1.25 μl Ampholine pH 3.5-9.5 (Pharmacia Biotech, n. 80-1127-15) 
105 μl IPG Rehydration solution 
 
•  Load sample in the strip holder, put the strip (Immobiline DryStrip pH3-10, 7 
cm, GE Healtcare Europe) paying attention that gel side is in contact with the 
sample solution and cover the strip with Dry Strip Cover Fluid (GE Healtcare 
Europe). 
•  Put the holder on the IPG Isoelectric Focusing Unit and set the following 
program: 
 
Rehydration for 10-12 h at 20°C 
120 µA/strip at 20°C 
S1:  500 V for 1 hr 
S2:  1000 V for 1 hr 
S3:  gradient voltage from 1000 V to 8000 V in 3 hr 
S4:  8000 V for 1 h 
S5:  50 V until stop 
 
At the end of the IEF experiment the value of Vh was > 8000 
 
IPG STRIP pH 3-10, 13 CM 
Sample preparation: 
100 μl IP from 293T cell protein extract (see section 5.2.2) 
  926 μl Bromophenol Blue 0.1 % 
1.6 μl Ampholine pH 3.5-9.5 (Pharmacia Biotech, n. 80-1127-15) 
143 μl IPG Rehydration solution 
 
•  Load sample in the strip holder, put the strip Immobiline DryStrip pH3-10, 
13 cm, GE Healtcare Europe) paying attention that gel side is in contact with 
the sample solution and cover the strip with Dry Strip Cover Fluid (GE 
Healtcare Europe). 
•  Put the holder on the IPG Isoelectric Focusing Unit and set the following 
program: 
 
Rehydration for 10-12 h at 20°C 
120 µA/strip at 20°C 
S1:  500 V for 2 hr 
S2:  1000 V for 2 hr 
S3:  gradient voltage from 1000 V to 8000 V in 6 hr 
S4:  8000 V for 2 h 
S5:  50 V until stop 
At the end of the IEF experiment the value of Vh was > 16000 
 
6.2.2. SECOND DIMENSION: SDS-PAGE 
•  Put the strip in the reduction solution for 10 min (agitation). 
•  Put the strip in the alkylation solution for 10 min (agitation). 
•  Load the strip on the surface of a SDS-polyacrylamide separating gel and 
cover the strip with an agarose solution containing Bromophenol Blue. 
•  Load the protein marker using a sample application piece. 
 
For the 7 cm strips the separating gel was 15% polyacrilamide and the 
electrophoresis was carried out in vertical electrophoretic cells Mini-PROTEAN II 
(BioRAD), applying 30 mA .  
 
  93For the 13 cm strips, the separating gel was 12% polyacrylamide and the 
electrophoresis was carried out in a vertical 18 cm electrophoretic cell, applying 24 
mA/gel constant, 180V.  
 
6.3. TRANSFER OF PROTEINS FROM SDS-
POLYACRILAMIDE GEL TO NITROCELLULOSE FILTER 
Proteins were transferred from polyacrylamide gel to nitrocellulose filter 
(OSMOMIC) using the Mini Trans-Blot (Bio Rad). 
 
Proteins from 6% polyacrylamide gel were transferred using the Transfer buffer 
with SDS at 30mA constant, 50V, 2W for 14-16 hr.  
 
Proteins from 12% polyacrylamide gel were transferred using the Transfer 
buffer without SDS at 120V constant, 340mA, 2W for 2 hr.  
 
Proteins from 15% polyacrylamide gel were transferred using the Transfer 
buffer without SDS at 120V constant, 340mA, 2W for 3 hr.  
 
Transfer was confirmed staining the nitrocellulose filter with Ponceau S as 
follows. 
•  Incubate the membrane in Ponceau Red Solution, 5min 
•  Remove the staining solution and wash the filter with deionized H2O until 
protein bands are visible 
 
  946.4. IMMUNOLOGICAL DETECTION OF PROTEINS 
IMMOBILIZED ON NITROCELLULOSE FILTERS 
(WESTERN BLOT) 
After Ponceau S staining the filters were used for immunodetection with specific 
antibodies as follows. 
 
•  Wash the membrane with 1XPBS-0.1%Tween 20 (PBS-T), 5 min 
•  Block aspecific sites incubating the membrane in 5% fat free dry milk PBS-
T, at RT for 1-3 hr  
•  Incubate the membrane with the primary abs diluted in 5% fat free dry milk 
PBS-T, 4°C, ON  
•  Wash the filter with 3 % fat free dry milk PBS-T, 5-10-5 min 
•  Incubate the membrane with the secondary abs diluted in 5% fat free dry 
milk PBS-T, RT, 1 hr  
•  Wash the filter with 3 % fat free dry milk PBS-T, 5-15-5 min 
•  Wash the filter with PBS, 4 times 5 min 
•  Detect immunoreactive proteins with ECL plus (GE Healthcare Europe) 
according to manufacturer’s instruction. Filters were exposed to 
autoradiographic X-OMAT AR Film (Kodak). 
 
For immunodetection with anti-CSTB abs all steps until wash after the 
secondary abs incubation were in 5% fat free dry milk PBS and Tween 20 was 
never added. 
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  PRIMARY ABS  SECONDARY ABS HRP 
CONJUGATED 
   Dilution    Dilution 
CSTB  Rabbit anti-cystatin b (Biogenesis)  1:300  Goat anti-rabbit IgG 
(Santa Cruz) 
RACK1  Mouse anti-RACK1 (BD Biosciences)  1:1500  Goat anti-mouse IgG 
(Santa Cruz) 
NF-L Goat  anti-NFL  (Santa Cruz)  1:300  Donkey anti-goat IgG 
(Santa Cruz) 
Goat anti-brain spectrin βI (C-19) (Santa 
Cruz)  1:300   Donkey anti-goat IgG 
(Santa Cruz)  β-spectrin 
Goat anti-brain spectrin βI (N-19) (Santa 
Cruz)  1:300  Donkey anti-goat IgG 
(Santa Cruz) 
HA  Mouse anti HA (F-7) (Santa Cruz)  1:2000  Goat anti-mouse IgG 
(Santa Cruz) 
HA  Rabbi anti HA (Y11) (Santa Cruz)  1:600  Goat anti-rabbit IgG 
(Santa Cruz) 
GAPDH
a Mouse anti-GAPDH (MAB374) 





a. In the second immunoblot 
 
6.5. SILVER STAINING OF POLYACRILAMIDE GEL 
•  Fix the proteins in the gel with MetOH 50%, Glacial acetic acid 12%RT, ON  
•  Rinse the gel with EtOH 50%, 3X15 min 
•  Sensitise the gel with Thiosulfate solution, 60 sec 
•  Wash the gel with milliQ H2O2, 3X20 sec 
•  Stain the gel with cold Silver solution, 15 min 
•  Wash the gel with milliQ H2O2, 2X20 sec 
•  Develop the staining with Developing solution until the desired intensity is 
achieved (usually not more than 2-5 min) 
•  Stop the developing reaction with the stop solution for at least 5 min 
•  Wash the gel with milliQ H2O2, 4X5 min 
•  Store the gel at 4°C in milliQ H2O2 
 
6.6. BRILLIANT BLUE G STAINING OF POLYACRILAMIDE GEL 
•  Fix the proteins in the gel with EtOH 40%, Glacial acetic acid 10%RT, ON  
•  Wash the gel with milliQ H2O2, 3X15 min 
  96•  Incubate the gel with 1X Colloidal brilliant blue G (Sigma), MetOH 34% RT, 
3 days 
•  Wash the gel with milliQ H2O2 
•  Store the gel at 4°C in milliQ H2O2 
 
7. PROTEIN IDENTIFICATION BY MASS 
SPECTROMETRY 
MS analysis was performed in collaboration with Fabrizio Dal Piaz at Salerno 
University. 
The bands were excised from the polyacrylamide gel, reduced, alkylated using 
iodoacetamide, and digested by trypsin. The resulting fragments were extracted 
and analysed by LC/MS on a Q-Tof Premier instrument (Waters, Corporation, 
Milford, MA-USA) coupled with a Waters 1065 HPLC apparatus (Waters 
Corporation). Peptides separation was carried out on a Proteus C18 (100x1 mm) 
column (Phenomenex, Foster City, CA-USA) using a linear gradient from 5% to 
60% of 1% Formic Acid, 0.05% TFA in CH3CN over 50 min (flow 50 µl/min). 
Mass spectra were acquired over a m/z range from 400 to 2000. 
The resulting fragments were extracted, purified using C18 ZipTip (Millipore) 
and measured by MALDI-TOF mass spectrometry on a Biflex instrument 
(Bruker, Bremen). 
 
8. PRE-ABSORPTION EXPERIMENTS 
24 μg/ml Anti-CSTB abs were mixed with 9.5 mg/ml protein extract from BL21 
cells expressing or non-expressing human CSTB, lyzed in buffer 1 (see section 
3.3.1.).  
  970.28 μg/ml Anti HA(F-7) abs were mixed with 9.5 mg/ml protein extract from 
BL21 cells expressing or non-expressing rat HA-CSTB, lyzed in buffer 1 (see 
section 3.3.1.).  
Following 1Hr incubation at RT the abs-protein extract mixtures were 
centrifuged 10 min at 17000g.  
The supernatants were collected and used for immuno-staining of the western 
blots. 
 
9. REDOX EXPERIMENTS.  
60 μg protein extract from 293T cells lyzed in buffer 1 (see section 3.3.1.) were 
used for each redox experiment. The reactions were stopped by addition of 
protein loading buffer with or without 50 mM β−METOH, as indicated. 
 
pH CURVE 
Protein extract from 293T cells lyzed in was incubated 5 min on ice, in 100 mM 
Tris HCl or 50mM Na carbonate/bicarbonate buffers at the indicated pH.  
 
GSH CURVE 
Protein extract was incubated 10 min at RT, in 100 mM Tris pH 7.5 with GSH at 
the indicated concentrations.  
 
H2O2 CURVE 
Protein extract was incubated 10 min at RT, in H2O2 at the indicated 
concentrations.  
 
  9810. SDS-FREE SIZE EXCLUSION 
CHROMATOGRAPHY (SEC) OF 293T 
PROTEIN EXTRACT 
Chromatography experiments were carried out in collaboration with Francesca 
Sparla and Paolo Trost at Bologna University (see also section 13).  
Approximately 400 μg protein extract from 293T cells lyzed in buffer 1 (see 
section 3.3.1.) were loaded on Tricorn Superdex®75 PC 3.2/30 (Amersham) 
equilibrated with 50 mM Tris pH 7.5 and run at a flow rate of 0.1 ml/min. 50 
μl fractions were collected. Calibration curve and graphic of the fraction OD 
against volume of elution are shown below. 
 
Tricorn Superdex®75 PC 3.2/30 Calibration curve: 
 
 ml  ml 
Bovine serum albumine  1.03  67000
Ovalbumin 1.12  43000
Chimotrypsinogen 1.27  25000
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Fractions were analysed by western blot as described in section 6. 
 
11. PURIFICATION OF CYSTATIN B MONOMER 
11.1. PREPARATIVE SDS-PAGE 
0.3 mg protein extract from E. coli transformed with pET16b-HA-CSTB wt or 
mutant, lyzed in buffer 1 (see section 3.3.1.) was loaded on preparative 15% 
SDS gels in the presence of 50 mM DTT. For each monomer 2 preparative gels 
were prepared. 
The gel was stained with Coomassie Blue R250 (Fluka) as follows:  
 
•  Fix and stain the proteins in the gel with Coomassie Blue R250 solution, RT, 
ON  
•  Destain with Destaining solution until the desired intensity is achieved 





Preparative 15% SDS-PAGE stained with Coomassie Blue R250: 4 μl Protein MW marker 
(Lane 1), 40μg protein extract from E. coli transformed with pET16b-HA (lane2), 300μg 
protein extract from E. coli transformed with pET16b-HA-CSTB wt (lane3). The monomer 
band to be excised is indicated.  
  10011.2. ELECTROELUTION 
HA-CSTB monomers were recovered from the polyacrylamide gel using the 
Model 422 electro-eluter (Bio Rad) and 3.5 kDa cut-off membrane caps 
(BioRAD). Electroelution was carried out in 1X protein running buffer, applying 
constant 8 mA for 5hr. Monomer from 0.6 mg protein extract was collected in 
500 μl of 1X protein running buffer. 
 
12. POLYMERIZATION ASSAY 
0.5 μl of electroeluted HA-CSTB monomer (see sec 11), wt and mutant, was 
incubated 10 min at RT with the indicated concentration of protein extract from 
E. coli transformed with pET16b-HA, lyzed in buffer 1 (see section 3.3.1.), and 
with equivalent concentration of column fractions as indicated. The reactions 
were stopped by addition of protein loading buffer with or without 50 mM DTT, 
as indicated. 
 
13. SEPARATION OF E. COLI PROTEINS 
BY COLUMN FRACTIONATION 
13.1. SEC WITH TRICORN SUPERDEX®200 PC 10/300 
Approximately 2 mg protein extract from E. coli transformed with pET16b-HA, 
lyzed in buffer 1 (see section 3.3.1.) were loaded on Tricorn Superdex®200 PC 
10/300 (Amersham) equilibrated with 50 mM Tris pH 7.5 and run at a flow rate 
of 0.5 ml/min. 500 μl fractions were collected. Calibration curve and graphic of 
the fraction OD against volume of elution are shown below. 
 
Tricorn Superdex®200 PC 10/300 Calibration curve 
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 ml  ml 
Bovine serum albumine  15.13  67000
Ovalbumin 15.91  43000
Chimotrypsinogen 16.87  25000




13.2. ION EXCHANGE CHROMATOGRAPHY (IEC) WITH 
TRICORN MONO Q 5/50 GL 
Fractions 24-31 from SEC with Tricorn Superdex®200 PC 10/300 were pooled 
and loaded on a Tricorn Mono G 5/50 GL anion exchange column  (Amersham). 
The elution was on a 0−1M NaCl in 16-column volumes gradient, in 20mM 
TRIS pH 7.9. 350 μl fractions were collected. Graphics of the fraction OD 
against volume of elution and of the elution gradient are shown below. 
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UV absorbance and ionic strength gradient traces of IEC with Tricorn Mono Q 5/50 GL of the 
pool of fractions 24-31 from SEC with Tricorn Superdex®200 PC 10/300. 
 
 
13.3. SEC WITH TRICORN SUPERDEX®75 PC 3.2/30 
Fractions 24, 26, 27, 28, 29 and 30 from the mono Q column were separately 
concentrated with 3 kDa cut-off centricon YM-3 (GE Healthcare Europe) and 
loaded on a Tricorn Superdex®75 PC 3.2/30 (Amersham) equilibrated with 50 
mM Tris pH 7.5 and run at a flow rate of 50 μl/min. 100 μl  fractions were 
collected. Calibration curve was as in section 10.1.The graphics of the fraction 
OD against volume of elution are shown below. 
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  10514. ANALYSIS OF CSTB EXPRESSION IN 
SKNBE CELLS 
SKNBE cells were transfected with eukaryotic expression vectors containing the 
wt and mutated CSTB sequences. Confocal Microscopy analysys performed in 
collaboration with Massimo Riccio at Modena and Reggio Emilia University.   
 
14.1. IMMUNOFLUORESCENCE ANALYSIS 
SKNBE cells, plated on mycroscopy cover glass and transfected as described in 
section 3.2.1. were immunofluorescence labeled as follows. 
 
•  Wash the cells with 1XPBS, 2X20 sec, RT 
•  Fix 20 min at 4°C in 1XPBS containing 4% paraformaldehyde 
•  Wash the cells with 1XPBS, 3X20 sec, 4°C 
•  Permeabilize5 min at RT in PBS containing 0.1% Triton X100 
•  Wash the cells with 1XPBS, 3X20 sec, RT 
•  Block aspecific sites with 3% BSA 1XPBS, 1 hr, RT 
•  Incubate with the primary abs diluted in 3% BSA 1XPBS, 1 hr, RT 
•  Wash with 3% BSA 1XPBS, 5X5min, RT 
•  Incubate with the secondary abs diluted in 3% BSA 1XPBS, 1 hr, RT 
•  Wash with 3% BSA 1XPBS, 6X5min, RT  
•  Add a drop of DABKO (Sigma) 
•  Store in the dark at 4°C. 
 
  PRIMARY ABS    SECONDARY ABS  
   Dilution      Dilution 
CSTB  Rabbit anti-cystatin b 
(Biogenesis)  1:10   Cy
TM5-conjugated donkey anti-rabbit abs 
F(ab’)2 fragment (Jackson). 
HA 
mouse anti HA (F-7) 
(Santa Cruz 
Biotechnology) 
1:50   FITC-conjugated sheep anti-mouse abs 





  10614.2. CONFOCAL MICROSCOPY AND CO-LOCALIZATION 
ANALYSIS 
The confocal imaging was performed on a Radiance 2000 confocal laser 
scanning microscope (BioRAD) having a red diod and an argon-krypton laser. 
For the individuation of the two signals, FITC and Cy5, samples were 
sequentially excited with the 488 nm line of a krypton laser and the 637 nm line 
of the red diod laser. The emission signals were separated by a dichroic mirror  
and detected by two photomultiplier tubes.  
The colocalization analysis was carried out by the LaserPix software (BioRAD) 
as described by [235].  
 
 excitation  λ emission  λ  
FITC  488 nm (blu) 525 nm (green)
Cy5  637 nm (red) 660 nm (rar red)
 
The in vivo GFP signal in SKNBE cells was obtained by exciting the sample 
with the 488 nm line of the krypton laser attenuated at 10%. The emission signal 
was detected through a long pass filter (LP; 520) placed before the 
photomultiplier tube. 
 
14.3. CELL COUNTS 
SKNBE cells were transfected with pEGFP-C1 constructs of wt and mutant 
CSTB. The transfected cells were counted at 24, 48, 72 96, 120, 144 and 168 Hr 
of incubation. The percentage of transfected cells was calculated for each 
experimental point using triplicate samples. The number of GFP
+ cells 
containing intracellular aggregates was also calculated. The mean of these 
values was normalized and expressed as percentage of aggregate containing 
cells over the number of transfected cells. The statistical significance of the 
differences between the experimental points was evaluated by Student’s t-test. 
  10715. SOLUTIONS  
15.1. SOLUTIONS FOR DNA AGAROSE GEL 
DNA MW MARKERS 
pBR322 DNA-Msp I Digest (New England BioLabs inc.), φX174 RF DNA/Hae 
III Fragments (Invitrogen), Lambda DAN/Eco RI + Hind III Marker (Promega) 
 
TAE 50X  
242 g Tris  
57,1 ml Acetic Acid (glacial) 
100 ml EDTA pH 8.0 
Add H2O to 1 L  
Autoclave 20 min at 120°C 
 
DNA LOADING BUFFER 10X 
0,4% Bromophenol blue (AppliChem) or Xylene cyanole FF sodium salt 
(AppliChem) 
50% Glycerol in H2O  
 
15.2. SOLUTIONS FOR BACTERIA CELL COLTURE 
LB (LURIA BROTH)  
10 g bacto tryptone (DIFCO) 
5 g yeast extract (DIFCO) 
10 g NaCl (Fluka) 
Add H2O to 1 L 
Adjust to pH 7.2 
Autoclave 20 min at 120°C 
 
TERRIFIC BROTH 
12 g bacto tryptone (DIFCO) 
24 g yeast extract (DIFCO) 
4 ml 100% Glycerol (Fluka) 
100 ml 170 mM KH2PO4 720 mM K2HPO4 Solution 
Add H2O to 1 L 
  108Adjust to pH 7.2 
Autoclave 20 min at 120°C 
 
KH2PO4 720 mM K2HPO4 SOLUTION  
23.1 g KH2PO4 
125.4 g K2HPO4 
Add H2O to 1 L  
Autoclave 20 min at 120°C 
 
2xYT  
16 g bacto tryptone (DIFCO) 
10 g yeast extract (DIFCO) 
5 g NaCl (Fluka) 
Add H2O to 1 L 
Adjust to pH 7 
Autoclave 20 min at 120°C 
 
AMPICILLIN 1000X 
1 g ampicillin sodium salt (Fluka) 
5 ml H2O 
5 ml EtOH  
 
KANAMYCIN 1000X 
0.2 g KANAMYCIN sulfate (Sigma-Aldrich) 
10 ml H2O 
 
SOB  
20 g bacto tryptone (DIFCO) 
5 g yeast extract (DIFCO) 
5 g NaCl (Fluka) 
10 ml 250mM KCl   
Add H2O to 1 L 
Adjust to pH 7 
Autoclave 20 min at 120°C 
 
SOC 
200 μl 1 M glucose (sterile) 
  10950 μl 2M MgCl2 (sterile) 
9,75 ml SOB 
 
15.3. SOLUTIONS FOR IP EXPERIMENTS 





Add H2O to 1 L 
Adjust to pH 7.4 
Autoclave 20 min at 120°C 
 
IP BUFFER 
150 mM NaCl 
20 mM Hepes-KOH pH 8 
0.5 %Nonidet P 40 
2 mM DTT 
0.4 mM EDTA pH 8 
 
15.4. SOLUTIONS FOR SDS-PAGE 
PROTEIN MW MARKER 
Precision Plus Protein Standards ass Blue (BioRAD) 
 




 a  
1.0 M Tris (pH 6.8)  
10% SDS  









  110SEPARATING GEL 
  6% SEPARATING 
GEL (10 ml) 
12% SEPARATING 
GEL (10 ml) 
15% SEPARATING 




























aCommonly 29% acrylamide and 1% N,IV'-methylene-bis-acrylamide;
 
 
PROTEIN RUNNING BUFFER 1X 
25 mM Tris  
190mM Glycine  
0.1% SDS  
 
PROTEIN LOADING BUFFER 1X  
(WITHOUT REDUCING AGENTS) 
TRIS pH 6.8 12mM 
Glycerol 5% 
SDS 1% 
Bromophenol Blue 0.02% 
 
TRANSFER BUFFER WITH SDS 
50 mM Tris, 380 mM Glycine, 0,1%SDS, 20% Methanol  
 
TRANSFER BUFFER WITHOUT SDS 
25mM Tris, 190mM Glycine, Methanol 20% 
 
PONCEAU S SOLUTION 1X 
0.2 g Ponceau S 
3 g trichloroacetic acid 
H2O2 to 100 ml 
 
  11115.5. SOLUTIONS FOR 2D-PAGE 
2X 2D-GEL BUFFER 
14 M Urea  
4 M Thiourea 
8 %CHAPS 
10 mM DTT 
milli-Q-H2O to final volume 
 
IPG REHYDRATION SOLUTION 
8M Urea 
2%CHAPS 
10 mM DTT  
milli-Q-H2O to final volume 
Store at –20°C. 
 
EQUILIBRATION BUFFER 
50 mM Tris-HCI-0.5 M pH 6.8 
6 M Urea 
30 % (v/v)Glycerol  
2%SDS 
milli-Q-H20 to final volume 
 
REDUCTION SOLUTION 
10 ml Equilibration buffer 
0.2 g DTT 
 
ALKYLATION SOLUTION 
10 ml Equilibration buffer 
0. 25 g Iodoacetamide 
10 μl Bromophenol Blue 0.1 % 
 
AGAROSE SOLUTION 
0.6 g agarose 
1.5 ml TRIS Ph 6.8, 1M 
50 μl Bromophenol Blue 0.1 % 
  112120 μl SDS 10% 
10.4 ml H2O 
 
15.6. SOLUTIONS FOR SILVER STAIN 
THIOSULFATE SOLUTION 




0.4 g AgNO3 
200 ml H2O 
 
Store in the dark and at 4°C, before use add 100 μl 37% Formaldehyde.  
 
DEVELOPING SOLUTION 
12 g Na2CO3 
4 ml Thiosulphate solution 
H2O to final volume 200 ml 
 
Store in the dark and at 4°C, before use add 100 μl 37% Formaldehyde.  
 
STOP SOLUTION 
18.6 g EDTA 
Add H2O to final volume 1L. 
Adjust to pH 7 with NaOH 
 
15.7. SOLUTIONS FOR COOMASSIE BLUE R250 STAINING 
COOMASSIE BLUE R250 SOLUTION  
0.4% Coomassie Brilliant Blue R250 (Fluka)  
20% MetOH 
80% H2O milli-Q 
 
DESTAINIG SOLUTION 
20% MetOH, 80% H2O milli-Q 
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-2623 cggttcaaac tgtctgctgc aaaccctggg tggcagtgtg ctgacttcct gcaccctagg 
-2563 caacggacct gtcacggtca cactcctagt gagcccctct tccgtctccc caggccacag 
-2503 cctccctcag gtgcacctga gcctcccctt cccattccag gcttttcccc ggctctgccc 
-2443 ccgcctgctg aggaatctcg gtcaacacaa gagaggaygg cgactccctt gtacagcaag 
-2383 tcctgaataa atsgtctttt gttctcattt gcgtgggctt tatttccaca gctgttatcc 
-2323 tcctatttgt aaaacggagg cacctgggac ccagctccag caaggagagt gaggatccsa 
-2263 ctccaggagg cacctcagga ccaaaggcct caaggccaac accttccacg gcacaagccc 
-2203 macagagctg caggacccgt acaagcagcg gaccatccct ttctcttctt gactatgttt 
-2143 tcccctgatg ctttgctttc cacatagaag agttttccat tttcgtgggg tcaactctgc 
-2083 cttcactcat tcaacaatga tggggggctc tgccccgctc cccccaggct tcaaccacac 
-2023 ctgactgccc acccctttgg gcccttccct gaagtgacag accaggctgt gccctggcag 
-1963 gtaagagaaa ggaccccaca acccattcat gggccgctcc agctggggcc ttgcatgcag 
-1903 gagcggacca gtccccctga gggacagccc ttgggtgggg gctctgggtc attttgagga 
-1843 gtcaatcaca ccaacaggtg cctagcacag gccccacccc caccccaaat aaggcaagcg 
-1783 acccttccct tccgcaggtg gtccagtcta acagaaaccc taaaccaaag ggactgtgtg 
-1723 gtggctcaag cctgtcatcc cagcactttg ggggatggat cgattttagc ctaggagttc 
-1663 aagaccagcc tgggcaatat agtgagactc catctctaca aaaacacttt ttaaaaaaat 
-1603 taggggtgca gtggtttatg ccaataatcc cagcactttg ggaggccgag gtggacagat 
-1543 cgctcagaag ttccagacca gcctgggtaa catggtgaaa ctctctgtct ctatatatgt 
-1483 gtgtggtagg gtgggcctgt ggtcccagct actatagcag ctgaggtggg aagatcgctt 
-1423 gagcccagga ggtccaggct gcaatgagtt gtgatcaggc cactgcaccc cagcctggcc 
-1363 aacagagcaa gactctgtca aaaaaaaaaa aaagaaagaa agaaaagagg tcaggtacgg 
-1303 tggctcacgc ctgtaattcc agcactttgg gagcccgagg caggtggatc acgaggtcag 
-1243 gagttcgaga ccagcctggc caatatggtg aaaccccgtc tctactaaaa acacaaaaat 
-1183 tagctgcgca tgaaggcgcg cgcctgtagt cccagctact cgggaggccg aggcaggaga 
-1123 atggtgtgaa ccccggaggc ggagcttgca gtgagccgag attgcgccac tgcactccag 
-1063 cctaggcgac agatccagac tccgtctcaa aaaaaaaaaa aaaaaggccg ggcgcagtgg 
-1003 ctcacacctg taatcccagc actttgggag gccaaggcgg gtggatcaca aggtcaggag 
 -943 atcgagacca tcctggctaa cacagtgaaa ccccgtctct actaaaaata caaaaattag 
 -883 ccaggtgtgg tggcgggcgc ctgtagtccc agctactcgg gaggctgagg caggagaatg 
 -823 gcgtgaaccc gggaggcgga gcytgcagtr agccgagatc gcgccactgc actccagcct 
 -763 gggagacaga gcgagactcc gtctcaaaaa aaaaaaaaaa aaaaaaaaag aaaagaaaag 
 -703 gaaagaaaga aaagaaatcc taaaacgcaa attccaccag agaaccctgc cttcttctca 
 -643 tccctctgat ctaccccctg cccccaccca gcctggagcg cgtgggcgcc gtctccccct 
 -583 ccctgggccc ctctgtccac ccccttcagc cttcagTGTT CTcggtcaca agcggtgatg 
                        ARE 
 -523 tccactgcag cccgcaCACC tgctcccgcg gggccgggac cccTGACccc TGACccctgc 
                MyoD?                          AP1     AP1 
 -463 agcgctgcgc cccgccctcc ctcgtgcgcg gcccggaccc cgccaccctg caggattgcg 
 -403 cctactccga ctgccccttc cctatcgtcc caccctgcgc gcccaaccca ccggcgacac 
                                                                   AP2? 
-343 ccggccgcgc ccccgccccg gtccgtgTGA Ctcggcgccc ggaaagacga taccagcccc 
                  Sp1/GC?                    AP1 
 -283 gggagggggg cgctccctcc cgacaccagc gctgggcgcg gagacccagc ctgcggcgag 
 -223 tggtggccag gctccCCGCC CcgcgccCCG CCCcgcgccC CGCCCcgcgc gtcccttctt 
                  Sp1          Sp1          Sp1                 
 -163 gcggggccac cgcgaccccg caggggactc cgaagccaaa gtgcctcctc cCCGCCCctt 
Sp1 
                                            TRANSCRIPTION START             
 -103  ggttCCGCCC gcgcgtcacg TGACcccagc gcctacttgg gctgaggagc cgccgcgtcc 
                      Sp1              AP1 
                     TRANSCRIPTION START 
       
EXON 1 
     -43  cctcgccgag tcccctcgcc agattccctc cgtcgccgcc aag 
+1 atg atg tgc Ggg gcg ccc tcc gcc acg cag ccg gcc acc gcc gag acc cag cac atc gcc gac cag       
    M1  M   C  G4  A  P   S  A   T  Q   P  A   T  A   E   T  Q   H  I   A   D Q22 
 
+67   g tgggtgggcc gcggggacgg ggccggcccg gagtcctgcc ttagcctcag ggcgcggccg cggctcctgg 
138   agcgaaagaa gccgcttygg ccccgctgcg cacccctggg ctggcccggg ctgtggccgt 
198   gagaggcctc cctccgctcg ggcgctgcgc gcgagtgagc agcggggggc cgcgcctggg 
258   gcgccgctgg ggagacattg ggctccgctg aatacagcaa gggcgagtgg gaattgatag 
318   cccggagcag ggtgcggtcc ctgcatggac agtctctgag aggaaacccc agggatgagg 
378   cgcttctggt ttcaggcagg cagggtgatc gggcgtcgcc ggcgatggcg caggtgagca 
438   gccggctccg atctccacgg tgatccgata gcaagcgggt gggaagggtc tggctaaact 
498   gacttagcca ggcttcttgc taaaagtgga ttttacaagg aagtgcgcag gtggcctagg 
 
558   cgcttcagga gcccgactac agtttggcca agcaagaatc tttgtcaata tcctcatcta 
618   gttcgggaaa aaaatcatga gagagagtgc aagaggtccc cagtgataag gcacatgggt 
  114678   taaaaactta agtgtatctg cataaaaggt ccacaggttt ctttacatgc ttccgattct 
738   agcactgttt caaactgtaa gtctaaataa aaagttaaaa cacagaaaaa caagataaaa 
798   accgggctgg gttgcagatg gcaaccttcc ctgtgtctcg gtttcctcgt ctgtaaaatg 
858   gacgtcctgt tgctctgcgc ctgccagaag attctggagg ggctgaaatg agcaggtcat 
918   ctgtgcaaga agccccctcc ggtggagcac aggccaggcc cgcctcgctg tcatggttgg 
978   tgaccgacgg gatgccccaa gcaagaacag gtccaggcga tgctgaggcc tgtgkttttt 
1038  ttktttgttt ttgagackca gtctcactct tgcccagggt ggagtgcagt ggcacaatct 
1098  cggcccactg caacctccgc ttcccaggtt caagggattc tcctgcctta gcctcccgag 
1158  tagctgggat tgcaggtgct cgccaccacg cccagctaat ttttgtattt ttagtagaaa 
1218  cggggttttg ccatttggct aggctggtct caaactcctg acctcaagtg atccgcccac 
1278  ctcagcctcc caaagttctg ggattacatc cttgagccac cgtacccagc tggaactgtt 
1338  tttttctact ttattattag gctgacagtt taaatgtccc ttcagttgta agagacaatt 
1398  gtgtgaagag ccagtgtcag aatcgtgtgt gtgctcacat gcgtgcaagt tactctagca 
1458  ggagggaatc caagaagcca ctgagacatc ctcattctgt cccttctgtc taG 
 
EXON 2    1511  gtg agg tcc cag ctt gaa gag aaa gaa aac aag aag ttc cct gtg ttt aag 
            V23  R  S   Q  L   E   E  K E/y? N   K  K   F  P   V  F   K 
        gcc gtg tca ttc aag agc cag gtg gtc gcg gGg aca aac tac ttc atc aaG 
        A   V  S   F  K   S  Q46 V   V  A  G50  T   N  Y   F  I  K56 
 
1613  gtaga gtgtgggcct caggagggcc 
1638  tgccccgaac gggtgctggt aggaaaccgc ctgtgcaggc ccgggctgtg tggtcttagg 
1698  tgctggggcg ccctgtggct gccccctgag ataagcatcc tactgtgtgt gtccatcggc 
1758  ctttcaggag gactagggct tctggggagc taagaacccc aaggaaacaa gtgtgggatg 
1818  tgaggcatcc cctgcacatg caggagaaga caagattgtc ttcagctggc tgctaatgac 
1878  ctggaggggc gcagcaaggt gacttgggat cagaggcttc gctcactccg ctctcttccc Ag 
 
EXON 3 
19 gtg cac gtc ggc gac gag gac ttc gta cac ctg Cga gtg ttc cAa TCt ctc cct cat ga 40  a aac aag
   V57  H   V  G   D  E   D  F   V  H   L  R68  V  F  Q  S72  L P74 H75 E76  N   K 
ccc ttg acc tta tct aac tac cag acc aac aaa gcc aag cat gat gag ctg acc tat ttc tga
 P   L  T   L  S   N  Y   Q  T   N   K   A  K   H  D  E   L   T  Y  F98  *
 
2069  tcctgactt tggacaaggc ccttcagcca gaagactgac aaagtcatcc 
2118  tccgtctacc agagcgtgca cttgtgatcc taaaataagc ttcatctccg ggctgtgccc 
2178  cttggggtgg aaggggcagg attctgcagc tgcttttgca tttctcttcc taaatttcat 
2238  tgtgttgatt tctttccttc ccaataggtg atcttaatta ctttcagaat attttcaaaa 
                        3’ UTR      3’Downstream    
2298  tagatatatt tttaaaatcc ttacagattg cctcctttgt tttagacttt tttcttgctg 







In italic : region rich in alu sequences (-686/-1728). 
In pink: transcription start and stop 
Highlighted in yellow: dodecamer repeats and nt mutated in 
EPM1 patients. 
Secondary Structure of the protein: loop in blu, α-helix in green, 
β-sheet in orange. 
Question mark next to a transcription factor site: the binding is 
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